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Abstract 
 
Bovine Polyomavirus (BPyV) is a member of Polyomaviridae, a family of double 
stranded DNA viruses. When the virus was initially discovered it was thought to 
be of simian origin (Wognum et al., 1984), but further research indicated that the 
virus was of bovine origin and that primate cultures had been contaminated 
through the use of foetal bovine serum (Parry et al., 1983). Studies have also 
shown that cattle populations world-wide have been exposed to the virus, which 
does not cause significant pathogenicity (Nairn et al., 2003). In addition, 71% of 
veterinary surgeons, 50% of cattle farmers and 40% of abattoir workers tested 
positive for the presence of antibodies to BPyV (Parry et al., 1986). BPyV  
 
Very little investigative work has been carried out on bovine polyomavirus but the 
entire sequence has been published and shows similarities in genome 
organization to the non-rodent polyoma viruses, such as SV-40 (Schuurman et 
al., 1990).  In contrast to other polyomaviruses, BPyV has a relatively small 
genome although the significance of this has not been determined.  A reliable in 
vitro cultivation assay for BPyV has been established; however the mode of 
replication is significantly different to reported polyomaviruses. BPyV requires 6-
8 weeks of culture before virus replication is detected, even by sensitive methods 
such as quantitative polymerase chain reaction (QPCR) (Nairn et al., 2003).  
 
The main reasons for the concern surrounding BPyV are the exposure risk, the 
ability of the virus to jump species and its cell transforming capacity described by 
Schuurman et al (1992) in rodent cells transformed with BPyV. To investigate 
these observations, the aim of this thesis was to understand the role of BPyV 
large T antigen, which is known to be directly involved in the replication of BPyV.  
 3 
During this thesis levels of BPyV viral genome and large T mRNA were 
assessed by QPCR and Reverse Transcriptase-QPCR (RT-QPCR) during an 8 
week cultivation period. High titres of BPyV were only detected in cells 
supplemented with 1% FCS. BPyV was unable to grow in cells supplemented 
with 10% FCS, with only low titres of virus being detected within the first 3 
weeks. A direct correlation between the large T mRNA and viral replication in 
cells supplemented with 1% FCS was determined, with large T mRNA being 
detected immediately prior to exponential viral replication. In addition, cell 
cultures were assessed using SDS-PAGE and Western Blot techniques to detect 
proteins specific to large T mRNA and cyclin A (an S-Phase promoting factor). 
Results indicate that the large T antigen is able to force the cell to enter S-
Phase, when both cellular and viral DNA are replicated together.  
 
Detection of large T antigen was inconclusive during the cultivation period, 
although later experiments attempting to over-express the large T antigen did 
show the presence of this protein.  During this experiment, the over-expression 
of the large T antigen was shown to be toxic to cells, with cells showing 
vacuolation and death. In addition, an individual clone of BPyV was isolated and 
sequenced. The consensus sequence was translated into amino acid, and 
several differences observed, one in particular that could affect the replication 
initiation and efficiency.   4 
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Chapter 1 – Introduction 
 
Viruses are obligate intracellular parasites that can only replicate by infecting 
host cells and usurping the cellular machinery. Viruses in their simplest form 
contain a single molecule of nucleic acid and a protein coat, sometimes enclosed 
by an envelope composed of lipids, proteins, and carbohydrates. The nucleic 
acid of viruses can be present in one of two forms – Ribonucleic acid (RNA) and 
Deoxyribonucleic acid (DNA). 
 
There are many thousands of viruses that come in a variety of shapes and sizes. 
They are found to replicate in just about every cell type from the simplest 
bacteria to complex mammalian systems. Most viruses only infect specific types 
of cells in one host species, not generally crossing species barriers. The host 
range (which refers to the spectrum of host cells in which a virus can multiply) is 
usually determined by the specific attachment of viral proteins to the host cell's 
surface. Thus, if a host lacks the receptor for a virus or if the host lacks some 
component necessary for the replication of a virus, the host will inherently be 
resistant to the virus.  For example, mice lack receptors for Polioviruses and thus 
are resistant. Similarly, humans are resistant to plant and many animal viruses. 
The host range of a virus can also be determined by penetration, which unlike 
viral attachment and adsorption, is an energy dependent process (i.e. the cells 
must be metabolically active). Three main mechanisms are thought to be 
involved in this process: Translocation of the entire virus across the cell 
membrane, Endocytosis of the virus into intracellular vacuoles, and Fusion of the 
viral envelope with the cell membrane (requires the presence of a fusion protein).   
 
However, some viruses are able to cross this species barrier. Direct interactions 
between infected host species and recipient species (contact with saliva, nasal 
secretions and faeces) enables some viruses to be transferred to a new host.  In 
cell culture it is possible to infect human kidney cells with the RNA virus Murine 17 
Leukemia virus (MuLV) by direct cell to cell contact and a high multiplication of 
infection (MOI) (Byrne et al., unpublished data). As the MuLV buds from the 
human cells the tropism (i.e. the cell type that the virus is most likely to infect) will 
be changed. The ability of viruses to cross species barrier has been well 
documented recently, especially concerning the RNA virus Avian Influenza virus 
H5N1. 
 
1.1 DNA Viruses 
 
1.1.1 Structure 
 
DNA viruses range in size from 20 nanometers (e.g. Parvoviruses) to several 
hundred nanometers (e.g. Poxviruses). The nucleic acid genome may be single 
stranded (ssDNA) or double stranded (dsDNA) and the number of genes 
encoded can be limited to 2-3 genes (e.g. Parvoviruses) up to a number of 
hundreds (e.g. Poxviruses). All DNA viruses contain a protein shell enclosing the 
genetic material called a capsid, composed of subunits or capsomeres, which 
can be made from a single type or several types of protein. The capsid and 
genomic material is referred to as the nucleocapsid - which may have 
icosahedral, helical or complex symmetry (figures 1.1, 1.2 and 1.3).  
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Figure 1.1 – Example of icosahedral symmetry showing the subunits of the 
capsid. Polyomaviruses are examples of viruses with this type of symmetry.  
 
 
 
 
Figure 1.2 – Example of helical symmetry showing arrangement of the proteins 
and nucleic acid. Tobacco Mosaic Virus is a virus exhibiting this type of 
symmetry.19 
 
 
 
Figure 1.3 – Example of complex symmetry. This structure can not defined by a 
mathematical equation as can a simple helix or icosahedron. Poxviruses are 
examples of viruses with this type of symmetry. 
 
The capsid of some DNA viruses is enclosed by an envelope consisting of lipids, 
proteins, and carbohydrates, usually obtained by budding through the 
membranes of host cells. In other cases the envelope may be derived from other 
membranes such as those of the Golgi body or the nucleus. 
 
 
1.1.2 DNA viral infection 
 
The first step in the infection of a cell by a DNA virus is the attachment of the 
virus to the cell surface. Although DNA viruses have evolved varying methods, in 
general the viral attachment protein (or antitreceptor) recognizes specific 
receptors on the outside of the cell, which may be protein, carbohydrate or lipid.  
 
Once attached the virus enters the cell, uncoats to releases the genomic material 
and express their genes using specific host cell proteins. The viruses are then 20 
assembled and exit the cells. In some cases viral DNA can become incorporated 
in the host cell genome (provirus). The provirus is passively replicated along with 
the host genome and passed onto the cell offspring, with all descendents of the 
infected cell containing the provirus in their genomes. Under some 
circumstances such as changes in the host’s environmental conditions or health, 
the provirus can be activated and begins massive transcription of the viral 
genome. This can lead to the destruction of its host as the protein synthesis 
machinery is hijacked to produce more viruses.  
 
Viral infection of cells does not always result in viral replication; this may be due to 
infection with defective virus, or other mechanisms which are a feature of the host 
cell. Infection with viruses which can form latent infections such as herpes or 
polyomaviruses latency results from either infection of non-replicating cells or 
replication in conjunction with the host cell so that the cell cycle is not interrupted. 
The viral genome persists intact and at some later time may enter a productive 
acute infection phase (possibly due to immunosupression of the host) to ensure a 
spread of its progeny to a new host.  
 
1.1.3 Modes/Diversity of Replication 
 
The structure, function, host range, pathogenesis and particularly the replication 
strategy of DNA viruses varies dramatically from virus to virus, even within 
viruses of the same family. 
 
Parvoviridae are among the smallest and simplest of viruses. They have few 
functional genes, relying on the mechanisms and enzymes present in the cells to 
facilitate replication. A member of the parvoviridae, the dependoviruses, also 
requires a “helper” virus (adenovirus or herpesviruses) to replicate (figure 2). All 
parvoviridae are small (20-25 nanometers (nm)), single stranded non-enveloped 
DNA viruses approx. 5 kilobases (kb) in length containing only 4-5 genes (two 21 
non structural (NS1 and 2) and 2-3 structural proteins depending on the virus) 
that replicate and assemble in the nucleus.  
 
In contrast, poxviruses are large (200-400nm), complex double stranded DNA 
viruses of 130-300kb in length, containing approximately 250 genes that 
replicate and assemble in the cytoplasm by expressing their own DNA 
dependant RNA polymerase, allowing these viruses to replicate with minimal 
cellular resources (figure 3). The progeny of both types of virus are released by 
host cell disintegration, although some poxvirus particles may bud from the cell 
acquiring an extra membrane.  
 
These two examples highlight the contrast between size, complexity and modes 
of replication between DNA viruses. With the exception of the poxviruses, most 
viruses are heavily dependent on the host cellular mechanisms, with viral 
replication only possible when cells are replicating.  However, all DNA viruses do 
share a common requirement and that is to generate mRNA that can be 
translated into proteins in order to replicate their genomes. 22 
 
 
 
 
 
Figure 2 - Comparison of the genome organization of the Parvoviridae virus 
Human Parvovirus B19 and adeno-associated virus AAV-2 (Dependovirus). Note 
the difference in complexity between 2 viruses of the same family. (Adapted from 
J. Virol. Shade et al., 58 (3): 921).  
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Figure 3 - Example of poxvirus genome organization and some of the numerous 
genes that allow these viruses to virtually replicate independently of the cell. This 
figure highlights 12 functional genes in this short section of the viral genome, 
compared to the 3-5 functional genes present in the entire genome of 
parvoviruses. 
 
1.2 Polyomaviruses 
 
Polyomaviruses are the sole genus of virus within the family Polyomaviridae, 
which is a subfamily of the Papovaviridae family. They are widely distributed in 
nature and have been described in many mammals and birds. Polyomaviruses 
cause inapparent infections in most hosts, and although largely species specific, 
the primate polyomavirus SV-40 and BPyV have been shown to infect non-
primate and non-bovine cells, respectively (Wognum et al., 1984. Parry et al., 
1983). Polyomaviruses are small (40-50nm), non-enveloped, icosahedral in 
shape and contain single molecules of covalently closed, superhelical dsDNA. 
Table 1 illustrates the known polyomaviruses and the variety of primary host 
species.  24 
Table 1 –Polyomaviruses 
 
Virus  Abbreviation  Host 
BK Virus  BKV Human 
JC Virus  JCV Human 
Simian Virus 40  SV40 Rhesus  monkey 
Murine Polyomavirus
  PyV Mouse 
Hamster Papovavirus  HaPV Hamster 
Lymphotropic Papovavirus  LPV  African Green Monkey 
Budgerigar Fledgling Disease Virus BFDV Parakeet 
Bovine Polyomavirus  BPyV Cattle 
Murine Polyomavirus (Kilham virus)
  KV Mouse 
Baboon Polyomavirus 2  BPV-2 Baboon 
Rabbit Kidney Vaculating Virus  RKV Rabbit 
Simian Virus Agent 12  SA12 Baboon 
Rat Polyomavirus  RPV Rat 
 
1.2.1 Polyomaviruses and disease 
 
In the majority of cases Polyomaviruses only cause clinical symptoms in 
immunodeficient hosts (Barbanti-Brodano et al., 1998). Human polyomavirus 
(JCV and BKV) infection in humans is common with seroprevalence rates in the 
population of 65-90% being reached by the age of ten years (Polyomaviruses 
and Human Diseases, Nasimul Ahsan, 2006). The kidney is where the virus lies 
dormant for many years although in the majority of patients only a subclinical 
infection may result. However, in immunocompromised patients, the virus may 
reactivate and cause significant disease, especially in conditions that bring about 
T cell deficiencies (Knowles et al., 2006).  The human polyomaviruses are known 
to cause hemorrhagic cystitis in recipients of bone marrow transplantation (BKV) 
and progressive multifocal leukoencephalopathy (JCV) in immunocompromised 25 
patients, for example, with Human Immunodeficiency virus infection. The current 
antiviral agents are unsuccessful in treating polyomavirus-related illnesses, with 
current strategies concentrating on the modification and/or improvement in the 
patients’ immune system.  
 
The ability of the human polyomaviruses (JCV and BKV) to cross species has 
been documented in Syrian hamsters (Corallini et al., 1982. Stoner et al., 1986). 
Tumors were induced following intravenous inoculation of BKV in Syrian golden 
hamsters. The types of induced tumors, or neoplasms, included ependymomas, 
carcinoma of pancreatic islets, lymphoma, osteosarcomas, undifferentiated 
sarcoma, kidney and renal pelvis carcinoma (Corallini et al., 1982). Intracerebral 
inoculation of newborn Golden Syrian
 hamsters with JCV induced a broad range of 
tumors including
  medulloblastoma, astrocytoma, glioblastoma, primitive 
neuroectodermal
  tumors and peripheral neruoblasoma in more than 85% of 
inoculated
 animals (Del Valle et al., 2001). PCR analysis in the appropriate tissues 
of human cancer patients has suggested that JCV may be associated with colon 
cancer (Enam et al., 2002). 
 
The simian polyomavirus SV-40 was introduced into the human population in the 
mid 1950’s from contaminated poliovaccines, and evidence now indicates that 
SV40 may have been transmitted in humans, independent of the earlier 
administration of vaccine. SV40 infections of humans are associated with 
inflammatory kidney diseases and with specific tumor types: mesothelioma, 
lymphoma, brain, and bone (Barbanti-Brodano et al., 2004).  
 
Species tropisms of BPyV have been studied and growth in non-bovine cells has 
been documented. Studies have also shown that 60% of veterinarians in the 
Netherlands have antibodies to BPyV, although the significance of this at his point 
is unknown (Osterhaus et al.,  1993).The sequence homology shared among 
several polyomaviruses (JC, BK, SA12, and SV40) (Pipas, 1992) may indicate a 26 
shared ancestry, enabling polyomaviruses to infect several species, including 
humans.  
 
Approximately 60% of bovine sera (Schuurman et al., 1991), which is used in the 
production of biopharmaceuticals, have been shown to contain bovine 
polyomavirus sequences. However, it was not until recently that it was thought to 
be of concern to humans, and it is now recommended by regulatory authorities 
that any therapeutic that has been in contact with bovine derived reagents be 
screened (EMEA guidelines, 2002).  
 
1.2.2. Polyomavirus Genome Organisation 
 
The polyomavirus genome is divided into early and late regions, corresponding 
to the portions of the genome that are expressed during the early and late stages 
of infection. The viral genomes of polyomaviruses consist of circular DNA 
molecules of approx. 5000 nucleotides in length (figure 4).  
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Figure 4 – Genome organisation of the Polyomavirus SV-40. The centre of the 
figure illustrates the direction of the early and late phases, proceeding in different 
directions. Both phases are initiated at the origin of replication (ORI). Small and 
large T antigens are expressed during the early phase. The viral capsid proteins 
VP1, 2 and 3 are expressed during the late phase. The small agnoprotein LP1 is 
also expressed during the late phase and is thought to be involved in VP1 
localization and viral capsid assembly (Modified from Butel JS, Jarvis DL: The 
plasma-membrane-associated form of SV40 large tumor antigen: biochemical 
and biological properties. Biochim Biophys Acta 865:171, 1986).  
 
The non-coding region of polyomaviruses contains the origin of replication and 
the early and late promoter-enhancer sequences. Viral transcription proceeds 
clockwise and anti-clockwise and two phases of transcription are present - early 
and late. The early phase is initiated prior to viral DNA replication; the late phase 
being initiated following viral DNA replication.  
 28 
Early RNA transcripts are processed by splicing to form the mature mRNAs for 
the early proteins (the T (tumour) antigens). There are 3 types – Small, Middle 
(not all polyomaviruses express this antigen) and large T antigens. Little is 
known regarding the function of the small T antigen although it does increase the 
efficiency of viral replication (Cicala et al., 1994). Recent studies have provided 
more information concerning the small T antigen, also suggesting that the small 
T antigen modifies the viral chromatin by altering the temporal coordination of 
virus growth and the cell cycle (Dahl et al., 2007), possibly by interactions with 
protein phosphatase 2A (PP2A plays a critical role in the cellular processes of 
protein synthesis, DNA replication, transcription, and metabolism) that leads to 
the transactivation of several genes involved in S-phase induction (Kluckly et al., 
2007). Little is also known about the middle T antigen although it is thought to be 
important for cell transformations (Asselin et al., 1983).  
 
The large T antigen has been researched in more detail and functions directly in 
initiating viral replication. The large T antigen is also responsible for recruiting 
specific host cell proteins, blocking cellular anti-viral mechanism, and initiating 
viral replication (Brodsky et al., 1998). Studies have also shown that the large T 
antigen of JCV modulates the Wnt-signaling pathway via interaction with beta-
catenin, one of the most important components of the canonical Wnt pathway 
(Bhattacharyya et al., 2007). The canonical Wnt pathway describes a series of 
events that occur when Wnt proteins (known for their roles in cancer) bind to cell-
surface receptors.  
 
Viral DNA replication occurs in the nucleus during the late phase, where the viral 
capsids proteins VP1, VP2, and VP3 are translated. 
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1.2.3 Replication / Life Cycle of polyomaviruses (sourced from Fields Virology 
unless otherwise stated) 
 
1.2.3.1 Attachment 
 
Using SV40 as a model, the polyomavirus receptors appear to be major 
histocompatibility complex (MHC) class I antigens (Norkin, 1999). Host receptors 
for some polyomaviruses are not known, but most appear to contain sialic acid 
(haemagglutinin) and are widespread in many tissue/species. The VP1 antigen is 
thought to be responsible for receptor binding as anti-VP1 antibodies (Goldmann 
et al., 1999) and VP1 point mutations (Nakanishi et al., 2007) prevents binding of 
the virus.  
1.2.3.2 Entry and Uncoating 
 
The viral capsid proteins VP2 and 3 are myristylated and are believed to interact 
with cellular membranes to facilitate entry. Virions are taken up by endocytosis 
and are transported to the nucleus by the interaction of endocytic vacuoles with 
the cytoskeleton. 
 
Virus particles enter the nucleus by the nuclear pores where uncoating occurs. 
The remaining stages of the replication cycle all occur in the nucleus. It has been 
proposed that VP2 and VP3 antigens mediate the nuclear entry of viral DNA, and 
may also be involved in the uncoating process, although the details are unknown 
(figure 5) (Nakanishi et al., 2007).  30 
 
1.2.3.3 Functional Gene Expression and Genome Replication 
 
Inside the nucleus, the virus mini-chromosome (genome-histone complex) is 
transcribed by the host cell RNA polymerase II to produce early mRNAs. 
Because of the relative simplicity of the viral genome (and small number of 
functional genes), polyomaviruses are heavily dependent on the cell for 
transcription and genome replication. However, the viral genome contains cis-
acting regulatory signals (surrounding the origin of replication) which enable the 
virus to direct transcription, replication and the expression of the trans-regulatory 
proteins. These trans-regulatory proteins are produced by alternative splicing of 
the early T-antigens.  
 
The early gene promoter contains strong enhancer elements which cause it to be 
active in newly infected cells. It is thought that the small T-antigen is not 
essential for virus replication, but indirectly (i.e. it interacts with cellular proteins 
but does not bind directly to the virus genome) enhancing transcription from the 
late promoter. 
 
Following expression of the large T antigen in the nucleus, transcription of the 
early genes is repressed by direct binding of the protein to the origin of 
replication, preventing transcription from the early promoter and causing the 
switch to the late phase of infection. After viral replication has occurred, 
transcription of the late phase genes is initiated from the late promoter and 
results in the synthesis of the structural proteins. 
 
For efficient viral replication, it is imperative for the host cell to enter the 
synthesis phase (S phase), when both cellular and viral DNA are replicated 
together. The S phase is a period in the cell cycle during interphase, between the 31 
G1 and G2 phases. At the beginning of the S phase, each chromosome is 
composed of one coiled DNA double helix molecule, which is called a chromatid. 
At the end of this stage, each chromosome has two identical DNA double helix 
molecules, and therefore is composed of two sister chromatids. During S phase, 
the centrosome is also duplicated. These two events are unconnected, but 
require many of the same factors to progress. The end result is the existence of 
duplicated genetic material in the cell (and viral genomic material), which will 
eventually be divided into two. ‘Protein to protein’ interactions between T-antigen 
and DNA polymerase-alpha directly stimulate replication of the virus genome, 
also inactivating the tumour suppressor proteins causing G1-arrested cells to 
enter S phase.  
 
Adherent cells that are grown in flask systems will often become ‘contact 
inhibited’ and will stop growing (e.g. Madin Darby Bovine Kidney (MDBK) cells), 
while other cell types will overgrow and die (e.g. Vero). In the case of MDBK 
cells, the cells will not enter S-phase, remaining in G1 phase until they are 
passaged. If cells are in G1 phase, then polyomaviruses will be unable to 
replicate. Therefore, in addition to increasing transcription, another important 
function of the T-antigen is to alter the cellular environment by inducing S-phase.  
1.2.3.4 Assembly/Maturation and Release 
Polyomavirus structural proteins contain 'nuclear localization signals' which 
results in their accumulation in the nucleus, where they migrate after being 
synthesized in the cytoplasm. Assembly occurs in the nucleus, and since the 
structure of the virus is relatively simple, assembly & maturation of the particle 
are simultaneous. 
 
Some virus particles are exported to the cell surface in cytoplasmic vacuoles, 
with the remaining virus particles being released when the cell undergoes lysis. 32 
Mechanisms of cell injury are not clear, but cell death is not uncommon due to 
the severe interference with normal cellular functions. The complete replication 
cycle for most polyomaviruses takes 48-72hours (depending on MOI). 
 
 
 
 
 
Figure 5 – The life cycle of SV-40. Figure highlights the attachment, entry, 
uncoating, replication and assembly of SV-40. Also note the interaction of the 
early and late translation products (T antigen and viral capsid proteins) (Adapted 
from Fields Virology). 
 
1.3 Bovine Polyomavirus  
 
Bovine polyomavirus was originally known as Stump tailed macaque virus 
(STMV) (Reissig et al., 1976) which, along with some closely related 
polyomavirus isolates, was originally isolated from monkey kidney cell cultures.  33 
It was first thought that the monkeys from which the virus was isolated from were 
the natural hosts, but subsequent work by Parry et al in 1983 and Wognum et al 
in 1984 showed that antibodies against BPyV could not be detected in 
Cynomolgus Macaques (high levels were detected in cattle). In addition, the 
isolation of the virus from bovine kidney cell cultures (Coackley et al., 1980), and 
assessments of viral morphology strongly suggested that all the viruses 
mentioned were of bovine origin (Schuurman et al., 1991). It is now thought that 
bovine polyomavirus is probably the most ancient of all mammalian 
polyomaviruses (Gottlieb at al., 2001). BPyV does not cause significant 
pathogenicity in cattle and no disease has yet been ascribed to the agent (Nairn 
et al., 2003). 
 
The genome of BPyV has been shown to be similar in organisation (Schuurman 
et al., 1990) (but not sequence homology – only 15%) (Pipas, 1992) to the non 
rodent polyoma viruses, such as SV-40, and consists of a circular DNA molecule 
of 4697 nucleotides which makes it the smallest polyomavirus genome 
sequenced to date (figure 6). Like all polyomaviruses viral replication occurs in 
two distinct phases; early and late gene expression, separated by genome 
replication. However, the early region of BPyV seems to have an uncommon 
organisation. In contrast to the characteristic presence of only one intron of 250 
to 400 nucleotides, two small introns separated by 80bp have been identified in 
the early region encoding the large T antigen (Schuurman et al., 1992). It has 
been suggested that one of the small introns identified in the large T antigen was 
involved in the formation of the putative small T antigen (Schuurman et al., 
1990), however, no evidence has been found to confirm this and even to this day 
the ability of BPyV to code for the small T antigen is questionable. No evidence 
of middle t has been found so far, and it seems that only rodent polyomaviruses 
encode for this antigen (Gottlieb et al., 2001). 
 34 
In BPyV the large T antigen may be able to carry out the functions of a small T 
antigen, notably the interaction with PP2A, similar to that of the middle T antigen 
function of murine polyomavirus (Gottlieb et al., 2001).  
 
 
 
 
Figure 6 – Genome Organisation of Bovine Polyomavirus. Genome organisation 
is similar to SV-40 with an early and late phase, although not marked as clearly 
on this figure. The origin of replication is at the top of the diagram with the early 
phase proceeding anti-clockwise (T antigens), and late phase clockwise (viral 
capsids). Note the splice site present in the early phase for the expression of the 
large T antigen (Source – Schuurman et al., 1990). 
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1.4 BPyV large T antigen 
 
Of the early phase antigens that are produced during BPyV replication, the most 
critical is the large T antigen, which regulates both viral genome and host cell 
cycle replication. The large T antigen functions by acting directly on cellular 
proteins. Viral replication is initiated by the binding of the large T antigen to the 
origin of replication (ori) region of the BPyV genome; a process controlled by 
phosphorylation (Brodsky et al., 1998). As well as being responsible for initiating 
replication, the binding of the large T antigen is also thought to cause the cells to 
leave G1 phase and enter S phase, promoting both cellular and viral replication 
by deregulating protein 53 (p53) and members of the retinoblastoma family 
(Moens et al., 2007)).  
 
During viral replication the large T antigen has several other important functions. 
Following binding to the ori  region, the large T antigen then recruits cellular 
proteins such as polymerase α, primase, topoisomerase, and the DNA 
replication factor RPA through direct physical contact, at the same time also 
inhibiting the host cells anti-viral functions. The large T antigen also regulates 
transcription control, initiating the transcription of the viral capsid and cellular 
target genes (VP1, 2 & 3) (Brodsky et al., 1998). 
 
With the exception of BPyV, Polyomaviruses during the first 20 hrs after infection 
are spent driving the host cells into the S phase so that cellular proteins and 
mechanisms are available to initiate viral replication. It can be hypothesized that 
replication would not be possible if the large T antigen wasn’t present, or was in 
some way defective. A number of questions arise concerning the function of 
large T - would replication be possible if the levels of the large T antigen were 
too low? Would replication only be initiated when a sufficient amount of large T 
antigen (or defective large T antigen) had accumulated? Could this explain the 
delay of the in vitro amplification of BPyV? 36 
 
When the sequences of several large T antigens are aligned (using pairwise 
alignment), the overall amino acid identity varies between 15 and 80%. JCV, 
BKV, and SV40 are all closely related, with 75% homology. In contrast, the avian 
budgerigar fledgling disease virus (BFDV) and BPyV show the least identity (15 
to 35%) with other members of the group (figure 7). T antigens encoded by the 
remaining viruses, Lymphotropic polyomavirus (LPV), hamster polyomavirus 
(HaPV), K virus (KV), and PyV, show an intermediate level of homology (45 to 
55%) both with each other and with the SV40 large T antigen. One possible 
explanation for this is the evolution of the different viruses to interact with 
different hosts (Pipas, 1992).  
 
 
A. large T antigen conserved region 1 (cr1) 
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B. The highly conserved hexapeptide (HPDKGG) region 
 
 
Figure 7 – Alignment of polyomavirus large T amino acid regions. In SV40, the 
amino-terminal domain plays an essential role in both viral replication and 
transformation. Three sequence elements within the amino-terminal domain are 
conserved among the T antigens - conserved region 1 (cr1), conserved region 2 
(cr2) and the hexapeptide HPDKGG. Sequence homology between cr1 and 
HPDKGG are highlighted. BPyV and BFDV show the least degree of identity with 
other polyomaviruses, with between 15 and 35% homology (Adapted from Pipas, 
1992). 
 
For polyomaviruses the large T antigen is critical for replication, being 
responsible for many functions. The majority of polyomavirus research has been 
carried out on the simian polyomavirus SV-40. Does BPyV (and the BPyV large 
T antigen) also function in the same manner as SV-40?  
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1.5 Aims 
 
The use of media supplemented with bovine serum is widespread in biological 
and medical laboratories. The frequent detection of BPyV in commercial batches 
reported by Schuurman et al in 1991 indicates that there is a serious risk of not 
only contaminating cell cultures used for research, but also cell cultures used for 
the production of biopharmaceuticals. The downstream applications of these 
products are an obvious concern, especially since the link with SV-40 and 
cancers in humans were made, although the role of SV40 in carcinogenesis (in 
transplanted patients) may be minimal (Paracchini et al., 2006). With the 
possibility that SV-40 is involved in carcinogenesis the presence of another non-
human polyomavirus (BPyV) in serum used for the production of 
biopharmaceuticals is a concern.  
 
A reliable in vitro cultivation of BPyV (Nairn et al., 2003) has been established; 
however the mode of replication is different in comparison to other 
polyomaviruses. In this study BPyV required at least 5 weeks of continual culture 
in cells fed with media supplemented with 1% Foetal Calf Serum (FCS) before 
virus replication was detected. These results contradict the other models of 
polyomavirus replication which has shown that viral replication occurs in cells 
doubling at a high rate in the first 1-2 weeks.  
 
The aim of this thesis is to assess the levels of BPyV and large T antigen 
expression during an 8 week infectivity experiment (and to assess large T mRNA 
levels prior to exponential viral amplification) using cells fed with media 
supplemented in 1% and 10% FCS. The aim is also to understand what is 
happening within the cells during this period, in particular following exponential 
amplification.  
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1.6 Objective 
 
The objective of this project is to understand by what mechanism(s) the virus is 
maintained during the period of limited or no replication, and to investigate the 
role of the large T antigen in the initiation of replication observed 5-8 weeks after 
inoculation.  
 
Part A 
 
What levels of BPyV genome replication and large T mRNA expression are 
observed during the culture of virus on cells grown in 1% and 10% FCS? 
Indication of expression levels may explain why the virus requires 5-8 weeks 
before exponential replication is observed.  This will be assessed by initiating an 
in vitro assay with BPyV and MDBK cells and quantitating the expression of both 
BPyV viral genomes and large T mRNA. Novel Quantitative Polymerase Chain 
Reaction (QPCR) and Reverse Transcriptase QPCR (RT-QPCR) assays will be 
designed and validated prior to assessment.  
 
Part B 
 
Does the infection of cells that are growing rapidly result in eventual 
disappearance of the virus from the culture system? If so, would this be of any 
use to the biotechnology industry, reducing the need for expensive and time 
consuming pre-clinical safety testing? This will also be assessed during the 8-
week infectivity experiments.  
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Part C 
 
Most polyomaviruses replicate between 48 and 72 hours, and the increased 
concentration of the large T antigen has already been established in the 
replication of other polyoma viruses. Why is BPyV different? The objective of this 
experiment is to assess large T mRNA levels prior to the onset of viral 
replication. If the large T antigen is as critical as first thought, could a more 
efficient BPyV infectivity assay be utilised either for the detection of large T 
mRNA, or inoculation of material onto cells expressing high levels of large T 
antigen? This will be achieved by cloning BPyV large T mRNA into an 
appropriate vector for expression in MDBK cells.  
 
Part D 
 
The ability of other polyomaviruses to move the infected cell into S-phase to 
necessitate viral replication has been determined, but it is the same for cells 
infected with BPyV? If so, why does it take so long for this to be initiated? By 
using infectivity results, along with sequencing information, SDS-PAGE and 
western blot analysis this will be determined.  41 
Chapter 2 
Materials and Methods 
 
2.1 Reagents 
 
2.1.1 Bacterial Strains and Plasmids 
 
The Eukaryotic TA Expression Kit Bidirectional (Invitrogen) was used for the 
cloning of large T PCR products. This kit utilized the Taq polymerase non 
template-dependent activity that adds a single deoxyadenosine (A) to the 3’ ends 
of the duplex molecules. The pCR3.1 linearized vector supplied with this kit has 
single 3’ deoxythymidine (T) residues. This allows PCR inserts to ligate efficiently 
with the vector. After ligation, One Shot (TOP10F’) competent cells are 
transformed and individual recombinant plasmids analysed for orientation by 
sequencing. The recombinant plasmid with the correct orientation was purified 
for transfection into MDBK cells (ATCC # CCL-22). 
 
2.1.2 Oligonucleotides   
 
Primers and probes for Q-PCR analysis were synthesized by Applied 
Biosystems. TAGN Newcastle synthesized sequencing and conventional PCR 
primers. The orientation of the primers with respect to the target sequence is 
indicated below in tables 2, 3 and 4, with “f” representing sense orientation and 
“r” the antisense orientation. “p” represents probe. 
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Table 2 – Conventional PCR Primers 
 
 
Name   Primer Sequence  Target Sequence 
 
BPyVF AAGTCATGGAATTAACATCTG  BPyV  LargeT    f 
BPyVR CTCATCATTTTTCCAGAATAT  BPyV  LargeT    r 
Table 3 – Sequencing primers 
 
 
Name   Primer Sequence  Target Sequence 
 
LargeT1F ATGGAATTAACATCTGAGGAATATGAGG  BPyV  LargeT    f 
LargeT251F TCAATCAAGGCTTTGATGAGCA  BPyV  LargeT   f 
LargeT501F TATCCAGGCAGCCTACAAATGTAC BPyV  LargeT    f 
LargeT751F GTGCAAGAAGAAGAAAAGTCTGTAAATT BPyV  LargeT    f 
LargeT1001F CTGTGTTAGCAAAAAGGAGATTAGATATG  BPyV  LargeT    f 
LargeT1251F GCCTGTAAACTGTGGGAAAACTACA BPyV  LargeT    f 
LargeT1509F ACATCAAAATAAGGTGACTCAGATCTTC  BPyV  LargeT    f 
LargeT1751F AGGAATGTGTAGTCAAGTGGAAAGAGA  BPyV  LargeT    f 
LargeT1852R CCAGAATATTTTTTCCTTGTTCAATGT BPyV  LargeT    r 
LargeT1607R ACTTTTTGATACATACGGATTTTGACTG  BPyV  LargeT    r 
LargeT1360R TTCCTAATTCAAATGCCAGTCTTTC BPyV  LargeT    r 
LargeT1110R CCGAGCGCCAAACAAATC  BPyV  LargeT    r 
LargeT608R TTTTCCATTGCATTTACCCGAT BPyV  LargeT    r 
LargeT360R GGTGGCTTGACTTCCCGG  BPyV  LargeT    r 
LargeT110R TGCACCTTGCATGCCTTC BPyV  LargeT    r 43 
Table 4 – Q-PCR Primers and Probes 
 
 
Q-PCR Primers and Probes 
 
Name   Primer Sequence  Target Sequence 
 
BPyV large T-945F  TGGTATGGTGTCTTCTATGCTCAAG  BPyV LargeT  f 
BPyV large T-1016R   TTACAACTGCACCTGAAGCATGT BPyV  LargeT    r 
BPyV large T-971T   AGTATGTGACAATCCCAGACG BPyV  LargeT    p 
(MGB) 
 
SpliceLargeT-60F TGGCAATGCAGATACTTTGAAAA  BPyV LargeT mRNA  f 
SpliceLargeT-137R TCTTCATTCCCTCCTTTATCTGGAT  BPyV LargeT mRNA  r 
SpliceLargeT-86T  CATTCCTGAAGGCATGCAAGGTGCA  BPyV LargeT mRNA  p 
 
VP1 100F  Propriety Information  BPyV VP1    f 
VP1 120R  Propriety Information  BPyV VP1    r 
VP1 85 T  Propriety Information  BPyV VP1    p 44 
2.2 Preparation and Manipulation of Nucleic Acids 
 
2.2.1 General 
 
Experiments involving the handling of nucleic acids were performed in 
accordance with standard practices to avoid cross contamination. Separate 
air-spaces were used for reagent preparation, sample processing, manipulation 
and the amplification and analysis of PCR/QPCR/RT-QPCR products.  A one-
way system was in operation and no amplified products were taken into the air-
spaces used for sample preparation.  Sentinel controls for airborne 
contamination consisting of open tubes containing all of the reagents and 
primers for amplification were present at all stages of sample preparation.   
These were processed along with the test samples.  
 
2.2.2 DNA Extractions 
 
DNA extractions were carried out using a Qiagen QIAamp DNA Mini Kit 
(Qiagen) following Appendix A – ‘Protocol for Cultured Cells’. The Qiagen 
QIAamp DNA Mini Kit works on the principle that nucleic acid is adsorbed 
onto a silica gel membrane after appropriate adjustment to allow optimal 
binding conditions (in the presence of carrier nucleic acid where required). 
Residual contaminants were removed during several washes and purified 
nucleic acid eluted in elution buffer.  
 
2.2.3 Viral RNA Extractions from cells 
 
Viral RNA extractions from cells were carried out using a Qiagen RNeasy Mini 
Kit (Qiagen), following the protocol for animal cells. The RNA extraction 
principle combines the selective binding properties of a silica-gel-based 
membrane with the speed of microspin technology. Samples were lysed and 
homogenized in the presence of a highly denaturing guanidine isothiocyanate 
(GITC)-containing buffer, which immediately inactivated RNases. Ethanol was 45 
added to provide appropriate binding conditions, and the sample applied to an 
RNeasy mini column for binding to the membrane and clearing of 
contaminants. RNA was then eluted in water. 
 
 
2.2.4 Viral RNA extraction from supernatants 
 
Viral extractions from supernatants were carried out using a QIAamp Viral RNA 
Mini Kit (Qiagen), following the QIAamp Viral RNA Mini Spin Protocol. The 
QIAamp Viral RNA Mini Kits principle again combines the selective binding 
properties of a silicagel-based membrane with the speed of microspin 
technology. Samples were lysed under highly denaturing conditions to 
inactivate RNases. Buffering conditions were adjusted to provide optimum 
binding of the RNA to the QIAamp membrane, and samples loaded onto the 
QIAamp Mini spin column. The RNA bound to the membrane, and 
contaminants were efficiently washed away in two steps using two different 
wash buffers. RNA was eluted in RNase-free buffer.  
 
 
2.2.5 Plasmid DNA extraction 
 
Plasmid DNA was extracted using a Qiagen Plasmid Mini Kit (Qiagen), 
following the manufacturers instructions.  QIAGEN plasmid purification 
principles are based on a modified alkaline lysis procedure, followed by 
binding of plasmid DNA to QIAGEN Anion-Exchange Resin under appropriate 
low-salt and pH conditions. RNA, proteins, dyes, and low-molecular-weight 
impurities were removed by a medium-salt wash. Plasmid DNA was then 
eluted in a high-salt buffer and concentrated/desalted by isopropanol 
precipitation. 
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2.2.6 Agarose Gel Electrophoresis  
 
PCR amplification products were visualised by gel electrophoresis using 
agarose gels prepared with Analytical Grade Agarose (Sigma) using flat bed 
electrophoresis apparatus. Gels were made with 1% w/v agarose in pre-made 
1xTBE buffer (Sigma), and 0.1% GelStar Nucleic Acid Stain (Cambrex). PCR 
products were prepared in 10x loading buffer (Blue Juice - Invitrogen), 1xTBE 
and electrophoresed at approx 100v for approx 2 hours. Gels were observed 
using an Ultra Violet imaging system and photographs taken.  
 
2.2.7 Determination of Nucleic Acid Concentrations 
 
The concentration of nucleic acids was determined by spectrophotometry at 
260nm. An absorbance of 1.0cm
-1 was taken to be equivalent to 50mg/ml for 
DNA and 40mg/ml for RNA. For sequencing, the concentration of DNA (e.g. 
PCR products) was estimated by electrophoresing an aliquot of the DNA 
solution in an agarose gel (see 2.2.6) and comparing band intensities with that 
of known standards. 
 
2.2.8 Automated DNA Sequencing 
 
DNA sequencing was performed using an Applied Biosystems (ABI) ABI310 
Genetic Analyzer utilising the dideoxy method of DNA sequencing developed 
by Sanger et al 1977. BigDye Terminator v1.1 reagents were supplied by 
Applied Biosystems. 
 
2.2.9 Nucleotide and Protein Sequence Analysis 
 
Computer aided analysis of nucleotide sequences were performed using the 
DNASTAR and BioEdit suite of programs. 
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2.3 POLYMERASE CHAIN REACTION 
 
2.3.1 General 
 
Polymerase chain reactions (PCR’s) were carried out using Roche Taq 
Polymerase (Roche Diagnostics). PCR’s were performed using a Perkin 
Elmer Thermal Cycler (Applied Biosystems). In general, reaction conditions 
consisted of a 3 minute denaturation step at 95
0C, followed by 30-35 cycles of 
95
0C for 30 secs (denaturation), a 30 secs annealing step (5-10
0C below the 
estimated melting temperature of the primer), and 72
0C for 30-60 secs 
(extension/polymerisation). A final extension/polymerisation step of 72
0C for 
10 minutes was carried out.  
 
2.3.2 Prevention of Contamination 
 
Separate air-spaces were used for reagent preparation, sample processing, 
manipulation of any positive control material and the amplification and analysis 
of PCR products.  A one-way system was followed and no amplified products 
were removed into the air-spaces used for sample preparation.  Sentinel 
controls for airborne contamination consisting of open tubes containing all of 
the reagents and primers for amplification were present at all stages of sample 
preparation.  These are processed along with the test samples. 
 
2.3.3 cDNA Preparation 
 
cDNA was prepared from total RNA. The Superscript III First-Strand Synthesis 
for RT-PCR Kit (Invitrogen) was used to produce cDNA for a two-step PCR 
process using Oligo(dT)20 to prime the reaction.  cDNA was stored at -20
0C.  
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2.4 Eukaryotic Cell Culture 
 
2.4.1 Growth Medium and Cell Lines 
 
MDBK (ATCC # CCL-22) cells were used in this study. Cells were grown in 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitrogen) containing either 
1% or 10% foetal calf serum (FCS) (Invitrogen) previously screened for the 
presence of BPyV by QPCR and shown to be negative. All cells were grown 
at 37
0C and were either fed and gassed with 5% CO2 (for cells grown in 1% 
FCS) or passaged, fed and gassed with 5% CO2 (for cell grown in 10% FCS) 
weekly. 
 
2.4.2 Passaging of Cells 
 
Cells grown in T-75 flasks DMEM supplemented with 1% FCS were re-fed 
every 7 days. Supernatants (s/n) were harvested and the cell monolayer 
washed with 5ml of HBSS (Invitrogen). Cells were fed with fresh media and 
gassed with 5% CO2. Cells grown in DMEM supplemented with 10% FCS 
were passaged every 7 days. Supernatant was harvested and the cell 
monolayer washed with 5ml of HBSS and Trypsin-EDTA (Invitrogen), before 
incubating with 2ml Trypsin-EDTA at 37
0C. Once cells had detached from the 
monolayer 8ml PBS (Sigma) was added and 1ml returned to flask (1/10 split). 
Cells fed with fresh media and gassed with 5% CO2. Cells were incubated at 
37
0C.  
 
2.4.3 Infection of Cell Lines 
 
4ml of BPyV positive supernatant (2.5x10
6 ge/ml – see section 2.5.6) was 
prepared including polybrene (final conc. – 10ug/ml) (Sigma). Media was 
removed from cells (80-90% confluent) and inoculum added and incubated for 
2-3 hours at 37
oC. Inoculum removed, cells fed with fresh media and gassed 
with 5% CO2 and incubated at 37
oC. 
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Negative control flasks were ‘inoculated’ with 2ml media plus polybrene (final 
conc. 10ug/ml), and incubated for 2-3 hours at 37
oC. Inoculum removed, and 
cells fed and gassed – incubated at 37
oC. 
 
Heat Inactivated (HI) flasks were inoculated with 4ml of heat inactivated BPyV 
(2.5x10
6  ge/ml – incubated at 95
oC overnight) plus polybrene (final conc. 
10ug/ml), and incubated for 2-3 hours at 37
oC. Inoculum removed, and cells 
fed and gassed – incubated at 37
oC. Heat Inactivated controls are included in 
order to show that any positive signals in cells were due to infectious virus 
particles, and not from residual inoculum. 
 
2.4.4 Harvest of Culture Samples 
 
Flasks of cells grown in 1% FCS were harvested each week – s/n and cells 
(1% cells are not passaged further to initial findings that BPyV replicates on 
cells growing at a very low doubling rate). S/n from 10% cells was harvested 
and cells split 1/10, retaining the remaining 9ml cells for testing (approx 1 x 
10
7  cells). 140ul aliquots of s/n will be taken and stored at –20
oC with 
remaining s/n being stored at –80
oC.  Cells were spun down and re-
suspended in 1mls PBS and frozen at -80
0C. 
 
2.4.5 Cell counts 
 
Harvested cells were counted by adding 0.5ml of harvested cells (in 9ml for 
10% flasks and 10ml for 1% flasks) to 0.5ml of trypan-blue (Sigma). Cells 
from each flask were aspirated and added to a hemocytometer and counted x 
4, also recording viability (percentage of live cells compared to total cells) 
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2.5 Q-PCR (Quantitative Polymerase Chain Reaction) 
 
2.5.1 General 
The use of real time polymerase chain reaction (PCR) detection allows the 
quantitative determination of the copy number of a nucleic acid target 
molecule. TaqMan
® PCR detection utilises the 5' exonuclease activity of Taq 
polymerase to hydrolyse an internal TaqMan
® probe labeled with a 5’ 
fluorescent reporter dye and a 3’ quencher molecule.  As amplification of the 
target molecule proceeds, the reporter dye is released from the 5’ end of the 
probe, and an increase in fluorescence proportional to the increase in PCR 
product observed. Calculation of the target copy number is based on when 
amplification of the target is first detected on an ABI 7900HT SDS.  The 
7900HT system determines the threshold cycle (CT), defined as the fractional 
cycle number at which fluorescence passes above a calculated threshold 
baseline.  Absolute quantitation is performed by comparing the CT values 
obtained for the unknown samples against the standard curve generated by 
known numbers of target molecules.
 
 
2.5.2 Primer Design 
 
The area of interest (intron/exon junction of large T region (SpliceLargeT-60F, 
137R & 86T), Large T DNA (BPyV large T-945F, 1016R & 971T), VP1 region 
(VP1 100F, 120R & 85T) was inputted into ABI Primer Design software and 
appropriate primers and probe selected (see 2.1.2). 
 
2.5.3 Q-PCR/RT-QPCR Conditions 
 
Q-PCR reactions plates were cycled as follows. 
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PCR conditions - DNA targets 
 
  Stage  1:  50
oC for 2 minutes (AmpErase UNG incubation) 
 Stage  2:  95
oC for 10 minutes (AmpliTaq Gold™ activation) 
 
  40  cycles  consisting  of: 
 
  Stage  3:  95
oC for 15 seconds (denaturation) 
 Stage  4:  60
oC for 1 minute (annealing/extension) 
 
RT-PCR conditions – RNA targets 
 
  Stage  1:  48
oC for 30 minutes (reverse transcription) 
  Stage  2:  95
oC for 10 minutes (AmpliTaq Gold™ activation) 
 
  40  cycles  consisting  of: 
 
  Stage  3:  95
oC for 15 seconds (denaturation) 
  Stage  4:  60
oC for 1 minute (annealing/extension) 
 
 
2.5.4 Reagents 
 
The relevant primers and probes were added to TaqMan Universal PCR 
Master Mix, or TaqMan Universal RT-PCR Mix (including 40X superscript 
RT), and exogenous internal positive control (IPC) (see below). This mix is 
then aliquoted and the relevant amount of water (for sentinel), negative DNA 
(for Negative), extracted BPyV material (for test samples), and synthetic 
oligonuceotides (for positives) added. 
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2.5.5 Internal Control 
 
Exogenous Internal Positive Control (Applied Biosystems) is an exogenous 
internal positive control (IPC) reagent included in all QPCR (and RT-QPCR) 
master mixes.  The IPC reagents are included into the target reaction mix to 
establish that all negative PCR results are truly negative and not due to failed 
amplification. 
 
2.5.6 Positive Controls 
 
Positive controls (DNA and RNA) were manufactured as synthetic 
oligonucleotides (Eurogentec) that were designed to span the amplicon of 
each primer set, with an additional 5 bases in the event of any degradation to 
the control. Positive controls were supplied lyophilised and resuspended in 
the recommended volume by the supplier to produce the required 
concentration. This data was used along with Avagadro’s number to calculate 
the molecules/µl, which is equivalent to genome copies per/µl (or genome 
equivalents).  
 
 
2.6 Transfection of MDBK cells with large T mRNA 
 
2.6.1 Growth Medium and Cell Lines 
 
MDBK (ATCC # CCL-22) cells were grown in DMEM containing horse serum 
(Invitrogen). All cells were grown at 37
0C in vented flasks in a 5% CO2 
incubator.  
 
2.6.2 Kill Curve 
 
Cells were seeded in 6 well plates at 1x10
5  cells/ml (2ml per well) and 
incubated at 37
0C in a 5% CO2 incubator 24 hours prior to transfection. Cells 
were seeded in medium without antibiotics. 24 hours following seeding, cells 53 
were re-fed with 10% DMEM supplemented with G418 sulphate (Sigma) at 
concentrations between 5mg/ml and 0.1mg/ml. Cells were then incubated and 
observed for cell death. Ten days following seeding the concentration of 
G418 that had killed approx 95% was chosen as the selection concentration 
to be used following transfection (plasmid used for cloning and transfection 
contains resistance to G418 – only cells containing this insert will survive). 
The concentration that was deemed to have killed approx 95% cells was 
800µg/ml of G418. 
 
2.6.3 Seeding and Transfection of Cells 
 
Cells were seeded in 6 well plates at 1x10
5  cells/ml (2ml per well) and 
incubated at 37
0C in a 5% CO2 incubator. Cells were seeded in media without 
antibiotics. Approx 24 hours following seeding the transfection reactions were 
prepared by diluting large T vector (1-2µg) and Lipofectamine 2000 reagent 
(Invitrogen) in OptiMEM (Invitrogen). A no-DNA reaction was also set up. 
Complexes were combined and incubated for 20 mins. Following incubation, 
reactions were added to the cells (80-95% confluent) containing media. 
Plates were incubated at 37
0C in a 5% CO2 incubator. 24 hours following 
transfection cells were re-fed with media supplemented with 800µg/ml of 
G418 for selection. Cells were returned to an incubator and observed daily.    
 
2.6.4 Ring cloning 
 
Ten days following transfection, when all no-DNA cells had been killed, 
colonies of cells were ‘ring cloned’ and transferred to fresh plates. Selection 
was added and cells incubated. Cells were split to larger flasks upon reaching 
confluency. 3 weeks following transfection, when cells had been bulked up to 
T-175 flasks, cells were harvested and tested for the presence of large T 
mRNA.  
 
 
 54 
2.7 Protein and Western Blot analysis 
 
2.7.1 General 
 
Sodium Dodecyl Sulphate – Polyacrylamide Gel Electrophoresis (SDS-
PAGE) and Western Blot analysis was carried out on cells harvested during 
the infectivity and transfection assays for the presence of the large T antigen 
and the cell cycle protein cyclin A involved in cell division. 
 
2.7.2 Preparation of protein for SDS-PAGE and Western Blotting 
 
500µl of each cell suspension was centrifuged at 450g for 5 mins and 
supernatant removed. Pellets resuspended in 200µl of RIPA buffer (Sigma), 
vortexed and incubated on ice for 5 minutes. Tubes were vortexed to 
resuspend and pelleted cells and quick frozen in liquid nitrogen. Samples 
stored at –80°C. 
 
2.7.3 Quantitation of protein 
 
Protein concentration was carried out using the EZQ Protein Quantitation Kit 
(Invitrogen).  Approximately 6µg of protein was used during SDS-Page and 
Western Blotting. 
 
2.7.4 SDS-PAGE Gel Staining 
 
Samples were analyses using reducing SDS-PAGE and stained using 
GelCode Blue Stain Reagent  (Pierce) the resulting banding patterns 
analysed, scanned and stored. 
 
2.7.5 Western Blotting 
 
Samples were analysed using reducing SDS-PAGE combined with Western 
blotting. The components to be stained are resolved during gel 55 
electrophoresis according to their molecular weight. The gel is then blotted on 
to a PVDF (Polyvinylidene fluoride) (Millipore) membrane where it is then 
either washed with SV40 large T Antigen (BD Biosciences) or Anti-cyclin A 
(AB-3) Mouse mAb (Calbiochem) primary antibodies and Anti-Mouse IgG (Fc 
specific) Peroxidase Antibody (Sigma) secondary antibody.  The membranes 
were developed using 3,3’-Diaminobenzidine (DAB) Enhanced Liquid 
Substrate System tetrahydrochloride (Sigma). The developed film was 
scanned and stored. 56 
Table 4 – Reagents 
 
Reagent           S u p p l i e r  
 
Eukaryotic TA Expression Kit Bidirectional  Invitrogen 
MDBK cells   ATCC 
QPCR/RT-QPCR Primers  Applied Biosystems 
PCR Primers  TAGN Newcastle 
QIAamp DNA Mini Kit  Qiagen 
RNeasy Mini Kit  Qiagen 
QIAamp Viral RNA Mini Kit  Qiagen 
Plasmid Mini Kit  Qiagen 
Analytical Grade Agarose   Sigma 
1xTBE buffer   Sigma 
GelStar Nucleic Acid Stain   Cambrex 
Blue Juice  Invitrogen 
BigDye Terminator v1.1 Reagents                      Applied Biosystems 
Taq Polymerase                   Roche  Diagnostics 
Superscript III First-Strand  Synthesis  Kit               Invitrogen 
Dulbecco’s Modified Eagle’s Medium                Invitrogen 
Foetal  Calf  Serum                 Invitrogen 
HBSS                    Invitrogen 
Trypsin-EDTA                   Invitrogen 
PBS                     Sigma 
Polybrene                   Sigma 
Trypan-Blue                       Sigma 
TaqMan  Reagents                 Invitrogen 57 
Synthetic oligonucleotides                  Eurogentec 
Horse  serum                   Invitrogen 
G418  sulphate                   Sigma 
Lipofectamine  2000                   Invitrogen 
OptiMEM                     Invitrogen 
SDS-PAGE  gels                 Invitrogen 
RIPA  buffer                     Sigma 
EZQ Protein Quantitation Kit                     Invitrogen 
GelCode Blue Stain Reagent                    Pierce 
PVDF  membranes                 Millipore 
SV40 large T Antigen                     BD Biosciences 
Anti-cyclin A (AB-3) Mouse mAb                  Calbiochem 
Anti-Mouse IgG (Fc specific) Peroxidase Antibody             Sigma 
3,3’-Diaminobenzidine                 Sigma 58 
Chapter 3 Assay Validation 
 
3.1 Principles of QPCR and RT-QPCR 
 
QPCR and RT-QPCR assays allow highly sensitive and specific detection of 
DNA and RNA sequences as well as offering the ability to quantify the target 
sequence. Specific instruments (ABI Sequence Detection Systems (SDS) 
7700/7900) are able to detect fluorescence during QPCR, allowing the ‘real-
time’ detection of PCR product accumulation via the hydrolysis of probes 
labeled with both a fluorescent reporter and a quencher. Quantitative data is 
derived from a determination of the cycle at which the amplification product 
signal crosses a pre-set detection threshold (threshold cycle, CT value), which is 
proportional to the amount of starting material.  
 
3.2 Assay Validation 
 
It is necessary that analytical procedures are appropriately validated to 
demonstrate that they are suitable for the intended use. The intention of the 
QPCR (and RT-QPCR) assays described in this thesis is to measure the 
amount of viral targets present in cell and supernatant harvests. In light of this 
information, the following validation characteristics have been evaluated for 
all QPCR and RT-QPCR assays utilised during this project. Assay validation 
was carried out in accordance with the ICH Topic Q2A and Q2B.  
 
3.2.1 Accuracy and Precision 
 
The accuracy of the assay was assessed by spiking known amounts of BPyV 
synthetic control into various substances such as water, MDBK DNA, and 
contaminants expected to be present in the testing products (trypsin and 
protein). The precision (and repeatability) of the QPCR’s was assessed by 
carrying out multiple runs with different operators and machines.  
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3.2.2 Specificity 
 
Specificity of the assay was assessed by testing each QPCR assay in the 
presence of components most likely to be present. For these QPCR’s DNA 
from various species was considered the most appropriate. Bovine (MDBK), 
Human (Human Placental DNA), and Rodent (Chinese Hamster Ovary) DNA 
were all used to asses specificity. Other polyoma viruses were unavailable 
during validation to determine specificity.  
 
3.2.3 Quantitation Limit, Linearity and Range 
 
The quantitation limit was assessed by analysing each positive control in 
replicates of 8, and determining the lowest concentration to show precise and 
accurate results. Linearity and range was assessed by analysing each 
standard in triplicate and determining the level that had a suitable level of 
precision, accuracy and linearity. The r
2 data generated refers to the squared 
coefficient of correlation and should be above 0.98 (recommended by the 
manufacturers of the TaqMan system). For the slope, an efficiency of 100% 
would relate to a value of -3.3. An acceptable reaction should have an 
efficiency between 90% and 110%, which corresponds to a slope between -
3.6 and -3.0.  
 
3.2.4 Primer/Probe Optimisation 
 
The primer and probe concentrations were optimised prior to validation to 
ensure optimal reaction concentrations. This is achieved by varying the 
concentrations of firstly the primers, and then the probe.  
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CHAPTER 4 - Results 
 
What levels of large T mRNA expression are observed with BPyV in 
comparison to other polyomaviruses such as SV-40, and does infection of 
rapidly growing cells with BPyV result in eventual disappearance of the virus 
from the culture system?  
 
What are the levels of large T mRNA prior to the onset of viral replication, and 
could a more efficient infectivity assay be developed by inoculating material 
onto cells expressing high levels of the large T antigen? The ability of other 
polyomavirus to move the infected cell into S-phase has been determined, but 
it is the same for cells infected with BPyV? 
 
4.1 Validation Results    
 
Primer and probe optimisation studies demonstrated the optimal primer probe 
combination to be 900:900:225µM (Forward Primer: Reverse Primer: Probe) 
for all assays. All assays were shown to be precise, specific, accurate and 
robust (assay sensitivity or linearity consistent using different batches of 
reagent on different days). The range was determined to be 1x10
1 to 1x10
6 
copies (or genome equivalents) per reaction for both QPCR’s, and 1x10
2 to 
1x10
6 copies/reaction for the RT-QPCR. The limit of quantitation for both 
QPCR’s was determined to be 1x10
1 copies per reaction, the lowest level at 
where precision and accuracy where observed. The limit of quantitation of the 
RT-QPCR’s was determined to be 1x10
2  copies per reaction. Quantities 
above 1x10
6 will still be reported for all assays but it should be noted that 
these results may not be accurate.  
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Figure 8 - Example of amplification plots (using large T mRNA primers and probes). 
Amplification plots for serial dilutions of large T RNA positive controls (tested in triplicate) are 
shown in green (marked with arrows). The highest concentration (1x10
8) is shown at the left 
of the plot, and the lowest concentration (1x10
2) is shown at the right of the plot.  The red line 
is referred to as the ‘threshold’ and is set as close to the exponential phase of amplification 
as possible. The red arrows are referred to as the ‘baseline’ and are set to minimize 
background signals. The point at which each dilution crosses the threshold is plotted in a 
standard curve (see figure 9) and quantities of unknowns calculated (Source – MSc 
experimental data). 
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Figure 9 - Example of a Standard Curve. The data from the amplification plot detailed in 
figure 8 was plotted in this standard curve. The CT numbers refers to the threshold cycle, 
which is the cycle that the amplification plot passes through the red threshold line (see figure 
8). The CT values of unknown samples are plotted against the curve (as shown with the red 
x’s) and quantities calculated. The statistical analysis of the slope indicates how linear and 
therefore quantitative the assay has been. The optimal slope is -3.3, Y-Inter 40 (as this assay 
was run over 40 cycles) and R
2 1.00. Slope values of -3.0 and -3.6, and R
2 values above 0.98 
are indicative of a linear assay. 
 
4.2 Are there differences between BPyV cultured on cells supplemented with 
1 and 10% FCS? 
 
Nairn et al documented in 2003 that the mode of replication for BPyV was 
unusual when compared to other polyomaviruses. It was observed that viral 
replication was only detected after 5-8 weeks of continuous culture (with no 
passaging) on cells doubling at a low rate in media supplemented in 1% 
Foetal Calf Serum (FCS) (Personal Reference, Nairn et al., 2003). What is 63 
the mechanism of replication, and is the inoculation and subsequent growth of 
BPyV on cells supplemented with 10% FCS different?  
 
To assess this an 8-week infectivity assay was initiated as detailed in section 
2.4 of the Methods and Materials (Eukaryotic Cell Culture). Supernatant and 
cells were harvested weekly from MDBK cells inoculated with BPyV and 
cultured in DMEM supplemented with 1% and 10% FCS. A heat inactivated 
(HI) control (which was inactivated by incubation at 95ºC for 24 hours) was 
also included in order to show that positive signals in cells were due to 
infectious virus particles, and not from residual inoculum. During preliminary 
studies (Personal Reference, Nairn et al., 2003), amplification signals were 
detected in cells not able to support BPyV viral replication. Inoculation of 
these cultures with HI inactivated BPyV generated similar results, proving that 
signals detected were due to residual inoculum, and not true amplification.  
 
Supernatants were harvested from flasks and nucleic acid extracted using a 
Qiagen DNA Mini kit (Section 2.2.2 of Materials and Methods) and tested by 
Q-PCR with primers and probes (BPyV LargeT-945F, 1016R and 971T) 
designed to the large T region of the BPyV viral genome. Extracted material 
was tested along with a synthetic DNA oligonucleotide diluted to represent 
10
1-10
6 genome equivalents in order to quantitate any viral genomes present. 
 
During the first 3 weeks of the infectivity assay BPyV viral genomes were 
detected in cells supplemented with both 1% and 10% FCS, although signals 
detected in 1% FCS samples were several logs higher following week 1. 
From week #’s 4 to 8 significant increases in BPyV viral genomes was only 
detected in cells grown in 1% FCS, with no viral sequences detected following 
week 3 in cells grown in 10% FCS (results illustrated in figure 10). 
 
In summary, infection of rapidly growing cells with BPyV (being passaged and 
fed with media supplemented with 10% FCS) resulted in the eventual 
disappearance of the virus from the culture system. In contrast it takes 4-5 
weeks of continuous culture in cells at a very low doubling rate, only being fed 64 
weekly with media supplemented with 1% FCS and not passaged, before 
exponential virus replication is detected. This is uncharacteristic among 
polyomaviruses in which the complete replication cycle takes 48-72 hours. 
Polyomaviruses only have 4-5 functional genes so rely heavily on cellular 
mechanism for replication. Therefore BPyV inoculated onto cells that are 
constantly multiplying (as they would be if grown in media supplemented in 
10% FCS and passaged regularly) should be replicating. In this period no 
viral replication was observed in the negative or HI controls (figure 11). 
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Figure 10 - Comparison of BPyV viral genomes in infected MDBK cells grown in DMEM 
supplemented with 1% and 10% FCS. Exponential amplification can be observed from wk 4 
in MDBK cells infected with BPyV and grown in media supplemented with 1% FCS. No 
amplification is observed from week # 4 in the 10% cultures. Data shown is from duplicate 
flasks tested and mean quantities calculated.  
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Figure 11 - Assessment of BPyV viral genomes (DNA) in negative and heat inactivated (HI) 
flasks. No amplification is observed in any of the controls. Data shown is from duplicate flasks 
tested. 
 
4.3 At what stage is large T mRNA expressed? 
 
During the same 8 week period that supernatant was harvested as detailed in 
section 4.2, cells were also harvested and total RNA extracted (as detailed in 
section 2.2.3) in an attempt to quantitate BPyV large T mRNA. 
 
Of the early phase antigens that are expressed during BPyV replication, the 
most critical is the large T antigen, which is thought to be directly responsible 
in the initiation of viral replication. Extracting RNA from cells harvested each 
week would indicate when large T mRNA was expressed but also show if 
there was any correlation between large T mRNA expression and BPyV viral 
genome replication. Extracted RNA was tested by RT-QPCR with primers and 
probes (SpliceLargeT-60F, 137R and 86T) designed to the large T region 
(intron-exon region in an attempt to only detect mRNA). RT-QPCR’s were 
analysed using a synthetic RNA oligonucleotide in the range of 10
1 – 10
6 
genome equivalents in order to quantitate mRNA targets. Samples were 
tested with and without RT (which reverse transcribes RNA to DNA) in order 
to distinguish between viral mRNA and viral genomic material. Primers and 66 
probe are designed in an intron-exon region, which should only amplify 
reverse transcribed RNA, but there is always a possibility that viral genomic 
material will also be amplified. Analyzing samples plus and minus RT allows 
determination of mRNA levels by subtracting the levels of minus RT reactions 
from plus RT reactions.   
 
Large T mRNA was not detected until weeks 4-5 of the culture period, when 
exponential replication of BPyV was also detected in the supernatant. The 
expression of mRNA from both flasks is similar, although mRNA expression 
was only detected week 4 in one of the duplicate flasks (results illustrated in 
figure 12).  
 
Virus inoculated onto cells grown in media supplemented with 10% FCS 
showed no production of large T mRNA, although detection of replicating 
virus in these cells during wk #’s 1-3 indicates that large T mRNA must be 
present, but potentially at a level lower than the limit of quantitation for the 
RT-QPCR assay (which is 1x10
2 copies per reaction) (results illustrated in 
figure 13). This may also be the case for cells grown in media supplemented 
with 1% FCS (figure 10). No mRNA expression was detected in the negative 
and heat inactivated cells (figure 14).   
 
It is possible that large T mRNA is expressed in the first 3-4 weeks of culture, 
but errors during transcription is resulting in large T mRNA being unable to be 
detected by the current primer/probe design. To determine if large T antigen 
was present in these initial harvests, cells were prepared for protein analysis 
by SDS-PAGE as detailed in section 2.7 (figure 15). 
 
Gels were set up with kD protein markers (lane 1 and 12), week 1 and 4 1% 
FCS MDBK negative controls from the 8-week infectivity assay (lane 2 and 3) 
and wks 1 - 8 1% FCS A MDBK samples from the 8-week infectivity assay 
(lanes 4-11). There is no protein band present in the samples that can 
correlated to the large T antigen (approx 65kD). It may be noted that the 
production of the large T antigen is heavily regulated, and therefore may not 67 
be at a level that would allow visualization. There is also the potential that 
some cellular proteins are masking the appearance of the large T antigen. 
Can these large T antigens be detected by western blot analysis with 
antibodies specific to large T?   
 
Western blots were prepared (section 2.7 of the methods and materials) using 
a large T specific primary antibody in an attempt to detect the large T antigen. 
Western blots were set up with a kD protein marker (lane 1), week 1, 4 and 8 
1% FCS MDBK negative controls from the 8-week infectivity assay (lane 2 - 
4), wks 2 - 8 1% FCS A MDBK samples from the 8-week infectivity assay 
(lanes 5-11), and a positive control (SV-40 infected Vero cells - lane 12). No 
bands were observed in lanes 2 (week 1, 1% negative control) and 6 (wk 4 
1% FCS A sample). No bands of the excepted size (approx. 65kD) were 
present in the remaining lanes. Faint bands are present above the 60kD 
marker for week 4 and 8 1% FCS negative control, and weeks 2, 3 and 5 – 8 
1% FCS A sample, however these must be non-specific due to observations 
in the negative controls (lanes 3 and 4) (figure 16). No cells were available for 
assessment due to poor cell growth for week 1 (1% FCS A or B samples) 
inoculated flasks. The only commercial large T antibody that was available 
was produced to the large T antigen of SV-40, and it was unclear if this 
antibody would also be specific to the large T antigen of BPyV. The SV-40 
large T antigen is approx 79kD. Confirmation of large T mRNA expression 
was shown by RT-QPCR, but subsequent experiments proved inconclusive, 
although several factors (low levels of expression, unspecific primary 
antibodies) may have been responsible for this.  
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Figure 12 - Data from duplicate flasks of MDBK cells grown in media supplemented with 1% 
FCS and inoculated with BPyV. Expression of large T mRNA can be observed wk 4 for the 
1%A harvests, and wk 5 for the 1%B harvests.  
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Figure 13 - Data from duplicate flask of MDBK cells grown in media supplemented with 10% 
FCS and inoculated with BPyV. Expression of large T mRNA was not detected in any of the 
harvests, although the detection of viral genomes at the start of the infectivity assay indicates 
that large T mRNA may have been present in the first 3 weeks.  
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Figure 14 - Data from negative and heat inactivated (HI) control flasks. No amplification is 
observed in any of the controls. Data shown is from duplicate flasks tested. 
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Figure 15 – SDS-PAGE using 8-week infectivity cell cultures (stained with GelCode Blue 
Stain). Approximately 6µg of protein was assessed. No bands are present that would indicate 
the presence of the large T antigen (65kD). Gels were run with kD protein markers (lane 1 
and 12), infectivity negative controls (MDBK) cultured in 1% FCS and harvested week 1 and 
4 (lane 2 and 3) and infectivity samples (MDBK) inoculated with BPyV, cultured with 1% FCS, 
and harvested week 1 to week 8 (lanes 4-11). Large T mRNA was detected by RT-QPCR in 
infectivity samples inoculated with BPyV and harvested week 4 to week 8 (lanes 7-11) (figure 
12).  
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Figure 16 – Western Blot analysis of 8-week infectivity cell cultures using SV40 large T 
primary antibody and Anti-Mouse IgG Peroxidase secondary antibody. Membranes were 
developed using the DAB Substrate system. Approximately 6µg of protein was assessed. No 
large T antigen bands are present (approx. 65kD). Faint bands are present just above the 
60kD marker in lanes 3-6 and 8-11, however must be non-specific due to observations in the 
negative controls (lanes 3 and 4). The large T antibody was raised against SV-40 large T 
antigen – it is unclear if this antibody will also be specific to BPyV. Western Blots were set up 
with a kD protein marker (lane 1), infectivity negative controls (MDBK) cultured in 1% FCS 
and harvested week’s 1, 4 and 8 (lane 2 - 4), infectivity samples (MDBK) inoculated with 
BPyV, cultured with 1% FCS, and harvested week 2 to week 8 (lanes 5-11), and a positive 
control (SV-40 infected Vero cells - lane 12).   
 
 
4.4 Are infected cells in S phase? 
 
During the same 8-week infectivity period that BPyV and large T mRNA 
sequences were assessed (sections 4.2 and 4.3), cells concentrations, 
viability and cyclin A expression were also assessed.  
 
If polyomaviruses require cellular mechanisms in order to replicate, and one 
of the functions of the large T antigen is to move cells into S phase to support 
viral replication, then performing cell counts at each harvest could potentially 72 
explain why we are only detecting high titres of virus in cells grown in media 
supplemented with 1% FCS. Assessing viability of cells during this 8-week 
infectivity period will also be of interest, to determine if viral infection is 
causing any cell death. Of particular interest are the cells grown in media 
supplemented with 1% FCS as they are not passaged for the entire 8 week 
experiment, and only fed with fresh media weekly.  
 
When exponential amplification is observed (4-5 weeks), all cell counts 
decreased gradually, with the exception of the cells grown in media 
supplemented with 1% FCS, which are the cells in which BPyV amplification 
is being detected (figure 17). Counts for cells grown in the 10% FCS B flask 
increased after this period, but from week 6 the cell counts gradually decline, 
unlike the cells grown in media supplemented in 1% FCS which remain   
constant (figure 18). There were no differences in cell viability which remained 
between 95% and 100% throughout the experiment (figure 19). Does the 
large T antigen induce S-phase allowing cellular and viral replication, as 
reported for other polyomaviruses? 
 
If BPyV does have the ability to move cells into S-Phase, which has been 
indicated by counting viable cells, then would it be possible to detect any S-
Phase promoting factors such as cyclin A or the absence of proteins such as 
cyclin E, which are destroyed during this phase? In order to determine if the 
cells were indeed moving into S-Phase towards the end of the infectivity 
period, samples that were previously analysed (section 4.2 and 4.3) for the 
presence of BPyV and large T mRNA were also assessed by western blot 
analysis (as detailed in section 2.7) with an antibody specific to cyclin A 
(figure 20). 
 
Western blots were set up with a kD marker (lane 1), week 1, 4 and 8 1% 
FCS negative MDBK control samples from the 8-week infectivity assay (lane 
2 - 4), wks 2 - 8 1% FCS A MDBK samples from the 8-week infectivity assay 
(lanes 5-11), and a positive control (HeLa cells - lane 12). Lanes 2 (week 1, 
1% negative control) and 7 (wk 4 1% FCS A sample) did not show any bands. 73 
However, in lanes 9 – 11 (wks 6, 7 & 8 1% FCS A samples), bands can be 
observed that are the size expected from cyclin A (approx. 65kD). These 
bands do not appear to be present in earlier harvests or negatives. Closer 
examination of the gels does show bands in other samples, but this is to be 
expected as there will be some growth or turnover of cells even in fully 
confluent cultures. These results confirm the theory that BPyV is able to move 
the cells into S-Phase to necessitate replication.  FACS (fluorescence-
activated cell sorter) analysis would have been a useful tool is confirming 
these observations, but unfortunately this technology was not available during 
this experiment.   
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Figure 17 - Cell counts for MBK cells inoculated with BPyV and maintained with media 
supplemented with 1% FCS. With the exception of the –ve cells, counts from the A and B 
flasks remained constant from wk’s 4-8, at the same time that exponential amplification was 
observed.  
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Figure 18 - Cell counts for MDBK cells inoculated with BPyV and maintained with media 
supplemented with 10% FCS. With the exception of counts carried out during week 6 of the 
10% B cells, counts gradually decreases from week’s 3-4. No viral amplification is detected 
from this time.  75 
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Figure 19 - Percentage viability for MDBK cells inoculated with BPyV and maintained with 
media supplemented with 1% and 10% FCS. % viabilities vary little over the 8 week infectivity 
assay.  76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 – Western Blot analysis of 8-week infectivity cell cultures using Anti-cyclin A 
primary antibodies and Anti-Mouse IgG Peroxidase secondary antibody. Membranes were 
developed using the DAB Substrate system. Approximately 6µg of protein was assessed. 
Bands are present at the size expected for cyclin A (65kD) in week 6, 7 & 8 harvests. Bands 
at this intensity are not observed in any other harvests. Western blots were set up with a kD 
protein marker (lane 1), infectivity negative controls (MDBK) cultured in 1% FCS and 
harvested week’s 1, 4 and 8 (lane 2 - 4), infectivity samples (MDBK) inoculated with BPyV, 
cultured with 1% FCS, and harvested week 2 to 8  (lanes 5-11), and a positive control (HeLa 
cells - lane 12). The difference in size between the MDBK and HeLa cyclin A protein is 
expected.   
 
 
4.4.1 Statistical analysis of data presented in section 4.2 to 4.4 
 
An attempt to apply statistical analysis to the data generated within these 
sections was unsuccessful due to low numbers of replicates and high 
variability within the data set. The student (paired) t-test could have provided 
meaningful data, but one of the preconditions for doing this test was that 
‘there should not be significant differences in the Standard Deviations from 
the data set’ (Wardlaw, 1985). It should be noted that if differences can 77 
biologically confirmed, which has been clearly demonstrated, then statistical 
analysis has limited use.   
 
  
4.5 Does sequencing of the large T antigen isolated from cultures differ from 
published sequences?   
 
As part of the experiment that was initiated to clone the large T mRNA for 
expression in MDBK cells (as detailed in section 4.6), a clone of large T 
mRNA was sequenced to confirm correct coding and orientation.  
 
During experiments detailed in sections 4.3, it was suggested that the large T 
antigen may have been defective, or differed in sequence from published 
data. Sequencing of this clone could potentially clarify this. The sequence of 
the large T mRNA (as detailed in section 2.2.8 of the Materials and Methods 
section) obtained from the clone was compared with the large T mRNA 
sequence published by Schuurman et al (figure 21) and subsequent 
sequences differences highlighted in grey. 
 
 
           ....|....| ....|....| ....|....| ....|....| ....|....|  
                           10         20         30         40         50              
BPyV(Schur)RC     ATGGAATTAA CATCTGAGGA ATATGAGGAG CTTAGGGGGC TCTTAGGAAC  
LargeT            ATGGAATTAA CATCTGAGGA ATATGAGGAG CTTAGGGGGC TCTTAGGAAC  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                           60         70         80         90        100             
BPyV(Schur)RC     CCCTGATATT GGCAATGCAG ATACTTTGAA AAAGGCATTC CTGAAGGCAT  
LargeT            CCCTGATATT GGCAATGCAG ATACTTCGAA AAAGGCATTC CTGAAGGCAT  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          110        120        130        140        150         
BPyV(Schur)RC     GCAAGGTGCA TCATCCAGAT AAAGGTAAAT ATATTTAGTA TTGATCTGTA  
LargeT            GCAAGGTGCA TCATCCAGAT AAAGGTAAAT ATTTTTAGTA CTGATCTGTA  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          160        170        180        190        200         
BPyV(Schur)RC     CATGCAAATC TTGTTTACAG GCAGTAAATC TGATTTTATT TTTAGGAGGG  
LargeT            CATGCAAATC TTGTTTACAG GCAGTAAATC TGATTTTATT TTTAGGAGGG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....|  
                          210        220        230        240        250         
BPyV(Schur)RC     AATGAAGAAG CAATGAAAAG ACTTCTGTAT TTGTATAATA AAGCAAAAAT  
LargeT            AATGAAGAAG CAATGAAAAG ACTTCTGTAT TTGTATAATA AAGCAAAAAT  
 
                   
 
 78 
     ....|....| ....|....| ....|....| ....|....| ....|....|  
                          260        270        280        290        300         
BPyV(Schur)RC     TGCTGCAAGT GCCACTACTA GCCAGGTATG GTATTTCTTA ATTATTGGAT  
LargeT            TGCTGCAAGT GCCACTACTA GCCAGGTATG GTATTTCTTA ATTATTGGAT  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          310        320        330        340        350         
BPyV(Schur)RC     ATATAAGCTT AAAAAATAAA AATATATACT TACCTAAGAT TTTCTGGTTA  
LargeT            ATATAAGCTT AAAAAATAAA AATATATACT TACCTAAGAT TTTCTGGTTT  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          360        370        380        390        400         
BPyV(Schur)RC     AGGTTCCAGA ATATGGCACC TCACAGTGGG AACAGTGGTG GGAAGAATTC  
LargeT            AGGTTCCAGA ATATGGCACC TCACAGTGGG AACAGTGGTG GGAAGAATTC  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          410        420        430        440        450         
BPyV(Schur)RC     AATCAAGGCT TTGATGAGCA AGATCTGCAT TGTGATGAGG AATTAGAGCC  
LargeT            AATCAAGGCT TTGATGAGCA AGATCTGCAT TGTGATGAGG AATTAGAGCC  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          460        470        480        490        500         
BPyV(Schur)RC     ATCAGATAAT GAGGAAGAAA ATCCGGCGGG AAGCCAGGCC CCGGGAAGTC  
LargeT            ATCAGATAAT GAGGAAGAAA ATCCGGCGGG AAGCCAGGCC CCGGGAAGTC  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          510        520        530        540        550         
BPyV(Schur)RC     AAGCCACCCC ACCCAAGAAA CCTAGAACAT CACCTGACTT TCCTGAGGTT  
LargeT            AAGCCACCCC ACCCAAGAAA CCTAGAACAT CACCTGACTT TCCTGAGGTT  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          560        570        580        590        600         
BPyV(Schur)RC     TTGAAAGAAT ATGTAAGCAA TGCTCTGTTC ACAAATAGAA CATATAATTG  
LargeT            TTGAAAGAAT ATGTAAGCAA TGCTCTGTTC ACAAATAGAA CATATAATTG  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          610        620        630        640        650         
BPyV(Schur)RC     CTTTATAATA TTTACTACTG CTGAGAAAGG AAAAGAATTA TATCCTTGTA  
LargeT            CTTTATAATA TTTACTACTG CTGAGAAAGG CAAAGAATTA TATCCTTGTA  
 
                ....|....| ....|....| ....|....| ....|....| ....|....|  
                          660        670        680        690        700         
BPyV(Schur)RC     TCCAGGCAGC CTACAAATGT ACATTTATTG CCTTATATAT GTATAATGGT  
LargeT            TCCAGGCAGC CTACAAATGT ACATTTATTG CCTTATATAT GTATAATGGT  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          710        720        730        740        750         
BPyV(Schur)RC     GATTCTGTTC TGTATATTAT CACTGTTGGA AAACATCGGG TAAATGCAAT  
LargeT            GATTCTGTTC TGTATGTTAT CACTGTTGGA AAACATCGGG TAAATGCAAT  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          760        770        780        790        800         
BPyV(Schur)RC     GGAAAATCTG TGTAGTAAAA AATGTACTGT GAGCTTCCTA CAAGCCAAGG  
LargeT            GGAAAATCTG TGTAGTAAAA AATGTACTGT GAGCTTCCTA CAAGCCAAGG  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          810        820        830        840        850         
BPyV(Schur)RC     GAGTTCTAAA ACCTCAGGAG GCCTATAATG TTTGCTGCAC ATTTGAACTT  
LargeT            GAGTTCTAAA ACCTCAGGAG GCCTATAATG TTTGCTGCAC ATTTGAACTT  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          860        870        880        890        900         
BPyV(Schur)RC     ATCTCCCAAA ACATACAAGG AGGTCTGCCA AGTAGTTTTT TTAACCCTGT  
LargeT            ATCTCCCAAA ACATACAAGG AGGTCTGCCA AGTAGTTTTT TTAACCCTGT  
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     ....|....| ....|....| ....|....| ....|....| ....|....|  
                          910        920        930        940        950         
BPyV(Schur)RC     GCAAGAAGAA GAAAAGTCTG TAAATTGGAA ACTCATTTCT GAATTTGCTT  
LargeT            GCAAGAAGAA GAAAAGTCTG TAAATTGGAA ACTCATTTCT GAATTTGCTT  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          960        970        980        990        1000        
BPyV(Schur)RC     GCAGCATTAA ATGTACAGAC CCCCTTTTAT TAATGGCATT ATATTTAGAA  
LargeT            GCAGTATTAA ATGTACAGAC CCTCTTTTAT TAATGGCATT ATATTTAGAA  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          1010       1020       1030       1040       1050        
BPyV(Schur)RC     TTTACAACTG CACCTGAAGC ATGTAAAGTA TGTGACAATC CCAGACGCCT  
LargeT            TTTACAACTG CACCTGAAGC ATGTAAAGTA TGTGACAATC CCAGACGCCT  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          1060       1070       1080       1090       1100        
BPyV(Schur)RC     TGAGCATAGA AGACACCATA CCAAAGACCA CACCTTAAAT GCTTTACTGT  
LargeT            TGAGCATAGA AGACACCATA CCAAAGACCA CACCTTAAAT GCTTTACTGT  
                  
              ....|....| ....|....| ....|....| ....|....| ....|....|  
                          1110       1120       1130       1140       1150        
BPyV(Schur)RC     TTCAGGACAG CAAAACTCAG AAAACCATAT GTAATCAGGC CTGTGATACT  
LargeT            TTCAGGACAG CAAAACTCAG AAAACTATAT GTAATCAGGC CTGTGATACT  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          1160       1170       1180       1190       1200        
BPyV(Schur)RC     GTGTTAGCAA AAAGGAGATT AGATATGAAA ACCTTAACTA GAAATGAATT  
LargeT            GTGTTAGCCA AAAGGAGATT GGATATGAAA ACATTAACTA GGAATGAATT  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          1210       1220       1230       1240       1250        
BPyV(Schur)RC     ATTAGTGCAA AGGTGGCAGG GCCTTTTTCA AGAAATGGAG GATTTGTTTG  
LargeT            ATTAGTGCAA AGGTGGCAGG GCCTTTTTCA AGAAATGGAG GATTTGTTTG  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          1260       1270       1280       1290       1300        
BPyV(Schur)RC     GCGCTCGGGG GGAGGAGCAT TTAGCCCACC GAATGGCGGC AGTTATGTGG  
LargeT            GCGCTCGGGG GGAGGAGCAT TTAGCCCACC GAATGGCGGC AGTTATGTGG  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          1310       1320       1330       1340       1350        
BPyV(Schur)RC     CTCAATGCCC TACATCCCAA TATGCCAGAT GTTATCTTTA ATTATATCAA  
LargeT            CTCAATGCCC TACATCCCAA TATGCCAGAT GTTATCTTTA ATTATATCAA  
 
            ....|....| ....|....| ....|....| ....|....| ....|....|  
                          1360       1370       1380       1390       1400        
BPyV(Schur)RC     GATGGTGGTT GAAAATAAAC CAAAACAGAG ATATCTCCTC TTAAAGGGGC  
LargeT            GATGGTGGTT GAAAATAAAC CAAAACAGAG ATATCTCCTC TTAAAGGGGC  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          1410       1420       1430       1440       1450        
BPyV(Schur)RC     CTGTAAACTG TGGGAAAACT ACAGTTGCTG CAGGCCTCAT AGGCCTGTGT  
LargeT            CTGTAAACTG TGGGAAAACT ACAGTTGCTG CAGGCCTCAT AGGCCTGTGT  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          1460       1470       1480       1490       1500        
BPyV(Schur)RC     GGGGGAGCTT ATTTAAATAT AAATTGTCCC CCTGAAAGAC TGGCATTTGA  
LargeT            GGGGGAGCTT ATTTAAATAT AAATTGTCCT CCCGAAAGAC TGGCATTTGA  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          1510       1520       1530       1540       1550        
BPyV(Schur)RC     ATTAGGAATG GCAATTGATC AATTTACAGT TGTGTTTGAA GATGTTAAAG  
LargeT            ATTAGGAATG GCAATTGATC AATTTACAGT TGTGTTTGAA GATGTCAAAG  
        80 
     ....|....| ....|....| ....|....| ....|....| ....|....|  
                          1560       1570       1580       1590       1600        
BPyV(Schur)RC     GTAAGAAATC CAGTAAATCC TCCCTTCAGA CTGGAATTGG TTTTGAAAAT  
LargeT            GTAAGAAATC CAGTAAATCC TCCCTTCAGA CTGGCATTGG TTTTGAAAAT  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          1610       1620       1630       1640       1650        
BPyV(Schur)RC     TTAGATAATT TAAGAGATCA TTTAGATGGT GCAGTCCCAG TAAACCTTGA  
LargeT            TTAGATAATT TAAGAGATCA TTTAGATGGT GCAGTCCCAG TAAACCTTGA  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          1660       1670       1680       1690       1700        
BPyV(Schur)RC     AAGAAAACAT CAAAATAAGG TGACTCAGAT CTTCCCACCT GGAATTGTTA  
LargeT            AAGAAAACAT CAAAATAAGG TGACTCAGAT CTTCCCACCT GGAATTGTTA  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          1710       1720       1730       1740       1750        
BPyV(Schur)RC     CCTGTAATGA ATATGACATA CCCTTAACAG TCAAAATCCG TATGTATCAA  
LargeT            CCTGTAATGA GTATGACATA CCCTTAACAG TCAAAATCCG TATGTATCAA  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          1760       1770       1780       1790       1800        
BPyV(Schur)RC     AAAGTAGAAC TACTGCATAA TTATAACTTA TATAAAAGTC TTAAAAATAC  
LargeT            AGAGTAGAAC TATTGCATAA TTATAACTTA TATAAAAGTC TTAAGAATAC  
                
              ....|....| ....|....| ....|....| ....|....| ....|....|  
                          1810       1820       1830       1840       1850        
BPyV(Schur)RC     TGAGGAAGTG GGCAAAAAAA GATATTTACA GAGTGGAATC ACCTGGCTCT  
LargeT            TGAGGAAGTG GGCAAAAAAA GATATTTACA GAGTGGAATC ACCTGGCTCT  
              
            ....|....| ....|....| ....|....| ....|....| ....|....|  
                          1860       1870       1880       1890       1900        
BPyV(Schur)RC     TATTACTCAT CTACTTTAGG TCTGTAGATG ATTTCACAGA AAAACTGCAG  
LargeT            TATTACTCAT CTACTTTAGG TCTGTAGATG ATTTCACAGA AAAACTGCAG  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          1910       1920       1930       1940       1950        
BPyV(Schur)RC     GAATGTGTAG TCAAGTGGAA AGAGAGAATT GAGACAGAGG TGGGAGATAT  
LargeT            GAATGTGTAG TCAAGTGGAA AGAGAGAATT GAGACAGAGG TGGGAGATAT  
 
                  ....|....| ....|....| ....|....| ....|....| ....|....|  
                          1960       1970       1980       1990       2000        
BPyV(Schur)RC     GTGGTTGTTA ACCATGAAAG AAAACATTGA ACAAGGAAAA AATATTCTGG  
LargeT            GTGGTTGTTA ACCATGAAAG AAAACATTGA ACAAGGAAAA AATATTCTGG  
 
                  ....|....|  
                          2010        
BPyV(Schur)RC     AAAAATGA--  
LargeT            AAAAATGA— 
 
 
Figure 21 – Reverse compliment (RC) sequence comparison of large T mRNA (cloned from 
supernatant harvested week 8 of an infectivity assay (not part of this project)) and the 
published large T mRNA sequence (Schuurman et al., 1990). Differences in nucleotide 
sequences are highlighted in grey. 
 
 
Several differences were observed between the 2 sequences, but to fully 
understand the impact of these differences both sequences were translated to 81 
the relevant amino acid sequence (using the spliced mRNA coding sequence) 
for further comparison.  
 
The translation highlighted 3 amino acid changes between the cloned large T 
mRNA and the amino acid translated from Schuurman et al’s published 
sequence. The change detailed at position 190 - ‘I’ to ‘V’ (Isoleucine to Valine) 
is a conservative change with both amino acids having nonpolar side chains 
that should not affect the functioning on the large T antigen. The change 
detailed at position 535 - ‘K’ to ‘R’ (Lysine to Arginine) – are both basic amino 
acids that again should not affect the functioning of the large T antigen. 
However, the change detailed at position 26 from ‘L’ to ‘S’ (Leucine to 
Serine), could potentially affect the functioning and structure of the large T 
antigen (results illustrated in figure 22). Leucine has a nonpolar hydrophobic 
side chain, whereas Serine has a polar hydrophilic neutral side chain. The 
sequence of amino acids in a protein and the chemical nature of their side 
chain allow proteins to do their function, and this Leucine to Serine change 
may affect the functioning of the large T antigen. Previous studies with yeast 
(Santos et al., 1996) and pBBR host range plasmids (Toa L et al., 2005) have 
reported that the Leucine to Serine change decreases the decoding efficiency 
of the transfer RNA (tRNA), and increases the plasmid copy number, 
respectively. The amino acid change observed with the cloned large T mRNA 
sequence has yet to be fully understood, although it should be noted that the 
Schuurman sequence was isolated from the wild. 
 
      
               ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                      10         20         30         40         50         60                 
LargeTschu   MELTSEEYEE LRGLLGTPDI GNADTLKKAF LKCKVHHPDK GGNEFAMKRL LYLYNKAKIA  
LargeTpb     MELTSEEYEE LRGLLGTPDI GNADTSKKAF LKCKVHHPDK GGNEFAMKRL LYLYNKAKIA  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                      70         80         90        100        110        120              
LargeTschu   ASATTSQVPE YGTSQWEQWW EEFNGFDEQD LHCDEELEPS DNNEEENPAG SQAPGSQATP  
LargeTpb     ASATTSQVPE YGTSQWEQWW EEFNGFDEQD LHCDEELEPS DNNEEENPAG SQAPGSQATP  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                     130        140        150        160        170        180           
LargeTschu   PKKPRTSPDF PEVLKEYVSN ALFTNRTYNC FIIFTTAEKG KELYPCIQAA YKCTFIALYM  
LargeTpb     PKKPRTSPDF PEVLKEYVSN ALFTNRTYNC FIIFTTAEKG KELYPCIQAA YKCTFIALYM  
 
 
              82 
      ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                     190        200        210        220        230        240           
LargeTschu   YNGDVLYIIT VGKHRVNAME NLCSKKCTVS FLQAKGVLKP QEAYNVCCTE ELISQNIQGG  
LargeTpb     YNGDVLYVIT VGKHRVNAME NLCSKKCTVS FLQAKGVLKP QEAYNVCCTE ELISQNIQGG  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                     250        260        270        280        290        300           
LargeTschu   LPSSFFNPVQ EEEKSVNWKL ISEFACSIKC TDPLLIMALY LEFTTAPEAC KVCDNPRRLE  
LargeTpb     LPSSFFNPVQ EEEKSVNWKL ISEFACSIKC TDPLLIMALY LEFTTAPEAC KVCDNPRRLE  
 
           
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                     310        320        330        340        350        360           
LargeTschu   HRRHHTKDHT LNALLFQDSK TQKTICNCAC DTVIAKRRLD MKTLTRNELL VQRWQGLFQE  
LargeTpb     HRRHHTKDHT LNALLFQDSK TQKTICNCAC DTVIAKRRLD MKTLTRNELL VQRWQGLFQE  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                     370        380        390        400        410        420           
LargeTschu   MEDLFGARGE EHLAHRMAAV MWLNALHPNM PDVIFNYIKM VVENKPKQRY LLLKGPVNCG  
LargeTpb     MEDLFGARGE EHLAHRMAAV MWLNALHPNM PDVIFNYIKM VVENKPKQRY LLLKGPVNCG  
        
      ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                     430        440        450        460        470        480           
LargeTschu   KTTVAAGLIG LCGGAYLNIN CPPERLAFEI GMAIDQFTVV FEDVKGKKSS KSSLLQTGIG  
LargeTpb     KTTVAAGLIG LCGGAYLNIN CPPERLAFEI GMAIDQFTVV FEDVKGKKSS KSSLLQTGIG  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                     490        500        510        520        530        540           
LargeTschu   FENLDNNLRD HLDGAVPVNL ERKHQNKVTQ IFPPGIVTCN EYDIPLTVKI RMYQKVELLH  
LargeTpb     FENLDNNLRD HLDGAVPVNL ERKHQNKVTQ IFPPGIVTCN EYDIPLTVKI RMYQRVELLH  
 
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                     550        560        570        580        590        600           
LargeTschu   NYNLYKSLKN TEEVGKKRYL QSGITWLLLL IYFRSVDDFT EKLQECVVKW KERIETEVGD  
LargeTpb     NYNLYKSLKN TEEVGKKRYL QSGITWLLLL IYFRSVDDFT EKLQECVVKW KERIETEVGD  
 
 
             ....|....| ....|.... 
                     610         
LargeTschu   MWLLTMKENI EQGKNILEK 
LargeTpb     MWLLTMKENI EQGKNILEK 
 
 
Figure 22 – Comparison of cloned large T amino acid (AA) sequence with Schuurman et al 
(1990) published sequence. Differences are highlighted in grey. 
 
 
4.6 – Does over-expression of the large T antigen result in high titres of virus?  
 
The experiment detailed in section 4.3 suggested that accumulation of the 
large T antigen may be a factor in the initiation of exponential viral replication. 
In theory, the inoculation of BPyV (or samples containing infectious BPyV) 
onto MDBK cells expressing high levels of the large T antigen may results in 
earlier detection of BPyV. To assess the effect of over expression, large T 83 
mRNA was cloned into a linearized plasmid vector and transfected onto 
MDBK cells as detailed in methods section 2.6.1 to 2.6.4  
 
Three weeks following transfection, cells began to detach from flasks, with 
remaining cells showing extensive vacuolation (figure 23). In an attempt to 
recover the experiment, cells were passaged and seeded in media with 
varying amounts of FCS - 1%, 5% & 10%. Cells were observed regularly and 
3-4 days following passage all cells showed signs of vacuolation. 6-7 days 
following passage cells started to detach in large sheets. It wasn’t apparent 
what was causing the cells to react this way, so remaining cells were 
harvested for RT-QPCR and protein analysis. Interestingly, vacuolation 
observed within the transfected cells is a classic sign of SV-40 cytopathic 
effect (figure 23). 
 
Total RNA was extracted from these cells and tested for the presence of large 
T mRNA using primers and probe (SpliceLargeT-60F, 137R and 86T) 
designed to the large T region of BPyV. All harvests were negative for the 
presence of large T mRNA, however the multi-components of the reactions 
(that show the different dye fluorescence levels during the assay) indicated 
that factors within the reactions were inhibitory. It is not unusual for samples 
containing high levels of ‘target’ to show inhibition and appear to be negative 
(with the assumption that large quantities of large T mRNA were present). 
Subsequent dilutions of the extracted samples did not detect large T mRNA 
and still indicated inhibition. 
 
To determine if the large T antigen was present in these cultures, and the 
mRNA potentially undetectable by RT-QPCR methods, samples were 
prepared for SDS-PAGE analysis as detailed in section 2.7 (figure 24). 
Protein was prepared and gels set up with kD protein markers (lane 1 and 
10), 8-week infectivity negative MDBK control cells cultured in 1% FCS (lane 
2), non transfected MDBK cells (lane 3) and transfected MDBK cell cultures 
(4 – 9).  
 84 
The banding patterns obtained from the infectivity assay (lane 2) were weak 
and direct comparison to the other lanes was not possible. However, a band 
of the expected size for the large T antigen (65kD) was present in lanes 4-9 
(MDBK cells transfected with BPyV) but not present in lane 3 (non transfected 
MDBK cells), suggesting that the transfection experiment was a success. It 
should be noted that expression of the large T antigen within the virus system 
is regulated, while the expression of the large T antigen within the vector 
system is highly promoted, potentially explaining vacuolation and inhibition 
observed during RT-QPCR. 
 
In addition to data obtained from RT-QPCR and SDS-PAGE analysis, 
western blot analysis (see section 2.7) was employed in an attempted to 
detect the expression of the large T antigen and cyclin A protein using 
specific antibodies (figures 25 and 26).  
 
The first western blot was prepared using the large T specific primary 
antibody in an attempt to detect large T protein expression. Western blots 
were set up with protein from the transfection experiments as detailed 
previously. Westerns were set up with a kD protein marker (lane 1), non 
transfected MDBK cells (lane 5), transfected cell cultures (6 – 11), and a 
positive control (SV-40 infected Vero cells - lane 12). Blanks were set up in 
lanes 2-4. Bands were present at a size expected for large T antigen in all 
samples, including the negatives. As detailed previously, the large T antibody 
is specific to SV-40, and specificity to BPyV is unknown.  
 
The second western blot was also prepared using a cyclin A specific primary 
antibody in an attempt to determine if transfected cells were in S-Phase. 
Western blots were set up as before (see above). In all samples, similar 
banding was observed, but no bands of the expected size for cyclin A (65kD), 
and no obvious banding differences between non-transfected and transfected 
cells. From this evidence it appears that the transfected cells were not in S-
Phase.  
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         A)    
 
          B)   
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C)   
 
 
D)   
 
Figure 23 – MDBK cells transfected with large T mRNA (A) and (B) showing vacuolation. (C) 
Vacuolation of African green monkey cells inoculated with SV40 (Picture taken 72 h after 
inoculation) (Source - Melnick et al., 1963). (D) Non-transfected healthy cells.  
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Figure 24 – SDS-PAGE of transfected cell cultures (stained with GelCode Blue Stain). 
Approximately 6µg of protein was assessed. Bands are present at the expected size that 
would indicate the presence of the large T antigen (approx. 65kD) in lanes 4-9 (marked with 
arrows). Gels were set up with kD protein markers (lane 1 and 10); infectivity negative control 
(MDBK) cells cultured in 1% FCS (lane 2), non-transfected MDBK cells (lane 3) and MDBK 
cells transfected with BPyV (lanes 4 – 9). 
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Figure 25 – Western Blot analysis of transfection experiment using SV40 large T primary 
antibody and Anti-Mouse IgG Peroxidase secondary antibody. Membranes were developed 
using the DAB Substrate system. Approximately 6µg of protein was assessed. No bands are 
present that would suggest the presence of BPyV large T antigens. Westerns were set up 
with a kD protein marker (lane 1), non transfected MDBK cells (lane 5), MDBK cells 
transfected with BPyV (6 – 11), and a positive control (SV-40 infected Vero cells - lane 12). 
Blanks were set up in lanes 2-4.  
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Figure 26 – Western Blot analysis of transfection experiment using Anti-cyclin A primary 
antibodies and Anti-Mouse IgG Peroxidase secondary antibody. Membranes were developed 
using the DAB Substrate system. Approximately 6µg of protein was assessed. No bands are 
present that would suggest the presence of cyclin A protein (65kD). Westerns were set up 
with a protein marker (lane 1), non transfected MDBK cells (lane 5), MDBK cells transfected 
with BPyV (6 – 11), and a positive control (HeLa cells - lane 12). Blanks were set up in lanes 
2-4. 
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Chapter 5 - Discussion 
The results of these experiments confirm that the large T antigen has an 
important role in the in vitro replication of Bovine Polyomavirus (BPyV).  Not 
only does an increase in large T mRNA correlate to an exponential increase 
in viral genomes, results also indicate that the large T is involved in moving 
the MDBK cells to S phase. It was demonstrated that high levels of BPyV 
were detected in cells supplemented with 1% FCS; with large T mRNA 
expression being detected immediately prior to exponential viral replication. 
Low levels of viral replication were only detected in the first 3 weeks in cells 
supplemented with 10% FCS. No large T mRNA expression was detected in 
these cells. An attempt to generate cells over-expressing the large T antigen 
was inconclusive, due to cell pathology. 
Analysis of DNA extracted from cells inoculated with BPyV and cultured for 8 
weeks (with 1% and 10% FCS) showed that exponential viral replication was 
only detected 5 weeks following inoculation onto cells grown in 1% FCS. 
BPyV was initially detected in cells grown in media supplemented with 10% 
FCS, but the titre of virus dropped each week until it was undetectable after 4 
weeks. It is unclear what caused the eventual disappearance of the virus from 
the culture system. In contrast, titres of virus obtained from cells grown in 
media supplemented with 1% FCS showed consistent growth over the first 3-
4 weeks before exponential replication was observed. This is uncharacteristic 
among polyomaviruses, in which the complete replication cycle takes 
between 48 and 72 hours. BPyV only has 4 known functional genes so relies 
heavily on cellular mechanisms for replication. Why is replication observed in 
cells that are only doubling at a low rate? What is the function of the large T 
antigen during this initial period of replication?  
BPyV may be removed from the culture system when grown in 10% FCS due 
to the cellular machinery replicating at a rate that does not allow the virus to 
effectively recruit the necessary cellular proteins to allow efficient viral 
replication. This scenario may also allow the cell to effectively combat BPyV 
viral infection, a mechanism which may be possible in vitro but is unlikely in 91 
vivo. Cells growing at a low doubling rate in 1% FCS (which is more similar to 
that likely in the in vivo situation) may allow the virus to recruit cellular 
proteins and allow expression of the necessary viral antigens. However, 
would the use of a culture system that is proven not to support the replication 
of BPyV be of any use to the biotechnology industry? The testing of 
biopharmaceuticals is costly and time consuming, and the culture of 
pharmaceuticals grown in a manner that would reduce the risk of BPyV 
contaminants would be beneficial, although the need to test for contaminants, 
especially BPyV, may always be required. 
To assess the possible roles of the large T antigen, mRNA was extracted 
from cells harvested during the 8 week infectivity assay. This analysis showed 
that large T mRNA was not detected until wk. 4 (in the A flask only – large T 
mRNA was not detected until wk. 5 in the B flask), a week before true 
exponential replication was observed, suggesting that the presence, if not the 
accumulation of large T mRNA was an important factor in the exponential 
replication of BPyV. No large T mRNA was detected in the cells grown in 
media supplemented with 10% FCS, although large T mRNA may have been 
present during this time but at levels too low for detection (signals suggesting 
viral replication were observed wk’s 1-3). 
If replication is being observed during these initial weeks, and viral replication 
is not possible without this antigen, then why is large T mRNA not being 
detected? The quantitation limit of the RT-QPCR assay is 10
2 large T mRNA 
molecules per reaction, and approximately 10
3  to 10
4  viral genomes per 
reaction (for cells supplemented with 1% FCS) are detected in the first 4 
weeks of the infectivity assay. This equates to a maximum of 0.1 - 0.01 
molecules of large T mRNA per virus particle. Is viral replication possible with 
such a small ratio of large T to virus? It is possible that the majority of large T 
mRNA generated during this time differs in sequence and is therefore not 
detectable by RT-QPCR (but still functional)? It may take several weeks and 
therefore multiple passages before non-defective large T antigens are 
produced resulting in the exponential replication observed. SDS-PAGE and 
western blot analysis was utilised at this point to determine if the large T 92 
antigen was indeed present in these initial weeks, but undetectable by RT-
QPCR. Results obtained were inconclusive, possible due to the non-
specificity of the large T antibody (raised against SV40). The expression of 
the large T antigen is regulated by the virus - is it maintained at low levels for 
a reason? The rate of large T antigen production in the initial infection period 
may be regulated in order to allow the virus (and therefore the large T 
antigen) to recruit the necessary cellular proteins and efficiently inhibit the 
antiviral mechanisms. We can hypothesize that accumulation of the large T 
antigen is critical for production of high titres of virus, but the antigen may also 
be regulated or latent during initial infection. If the virus is latent, then what is 
the switch to replication? Latent polyoma viruses have been shown to cause 
tumors in patients, but only when they become immunocompromised – how 
could this process be replicated in cell culture?  The virus may remain latent 
until the cells are confluent and doubling at a low rate before controlling the 
replication machinery (including the anti-viral mechanisms) of the cell. Results 
obtained suggest that the accumulation or regulation of the virus takes 
approximately 3-4 weeks. However, we can only hypothesize on the level and 
roles of large T antigen in these initial weeks, as results obtained from these 
experiments were inconclusive.  
To determine if the accumulation of large T antigen was a factor in 
exponential viral replication, MDBK cells were transfected in an attempt to 
generate cells continuously expressing high levels of large T antigen. The 
procedure appeared to be toxic to the cells, although SDS-PAGE analysis 
indicated a band of the expected size for the large T (65kD) antigen in all 
transfected cell cultures (no bands present in negative controls). Western Blot 
analysis was inconclusive. It is possible that large T mRNA is not being 
translated or folded incorrectly, therefore not being able to function efficiently. 
Interestingly, the vacuolation observed in the cells is a classic sign of SV-40 
cytopathic effect, never reported with BPyV. This may indicate that BPyV has 
a tighter control over the large T antigen than SV-40. Again, we can only 
hypothesize concerning the success of this experiment, but it should be noted 
that the vector is designed to heavily promote the inserted large T mRNA, 93 
which may be toxic to the cells. Production of large T antigen may need to be 
regulated to keep the infected cells alive, explaining why levels of large T 
mRNA are not detected in the early stages of the infectivity assay (but not 
why cell death is not observed in the later stages of the infectivity 
experiment). Cell death could have been due to the transfection procedure, 
but the vector used is specifically designed for expression in mammalian 
systems.  
How is BPyV able to replicate and produce such high titres of virus in cells 
supplemented with 1% FCS and doubling at a low rate? Does the large T 
antigen have a role in altering the state of the cell? It has been shown with 
SV-40 that the large T antigen is involved in moving the cells into S-Phase - is 
this also the case with BPyV?  
Counts from cells harvested during the 8-week infectivity assay indicated that 
following the point when exponential replication of BPyV was detected, all cell 
counts decreased gradually, with the exception of cells infected and grown in 
1% FCS.  Was the BPyV large T antigen moving these cells into S-Phase? 
SDS-PAGE analysis was inconclusive, but western blot analysis of these cells 
using an antibody specific to cyclin A showed a band of the expected size 
(65kD) present in harvests from week #’s 6, 7 and 8. On closer examination, 
faint bands of the same size can be observed in other harvests, but this is not 
unusual as some semblance of cell growth must be taking place. However, 
why does it take 6 weeks before we see the cells entering S-Phase? Does the 
large T antigen need to be at a level that allows it to alter the cells replication 
phases? Does the cell have to become confluent before large T antigen can 
be effectively expressed?  
In the process of generating a vector for expression in cells, a sample of 
BPyV virus, which had been cultured for 8 weeks and harvested, was cloned. 
As part of the cloning procedure, sequencing was carried out to confirm the 
correct sequence and orientation. This sequence analysis highlighted several 
base pair differences between the cloned large T mRNA and the published 
large T mRNA sequence (isolated from the wild). One of these differences 94 
resulted in an amino acid change from hydrophobic side chain to polar 
hydrophilic neutral side chain. This change could potentially affect the folding 
and functioning of the antigen. Studies have shown that this amino acid 
change can result in both the decreasing and increasing of replication 
efficiency. If this is an example of the type of large T antigen being expressed 
after 8 weeks of culture, then a high percentage of large T antigen mutants 
may explain why it takes 4-5 weeks to see exponential amplification of viral 
genomes. 
Since the start of this project, only 2 papers have been published on Bovine 
Polyomavirus. In February 2005 a paper was published concerning the 
‘Detection and molecular characterisation of bovine polyomavirus in bovine 
sera in New Zealand’ (Wang et al., 2005). This paper documents the 
detection of BPyV in 46 (70%) batches of FBS, 11 (32%) batches of calf sera 
and two (5%) batches of ABS/plasma, although similar results have been 
documented previously. The paper concludes that BPyV is a frequent 
contaminant (showing genomic variations) of commercial bovine serum in 
New Zealand, and that the incidence of BPyV in adult bovine serum products 
is much lower than in FBS and calf serum. The significance of the high 
prevalence of BPyV DNA in bovine serum products has been discussed 
previously. 
In December 2006 another paper was published concerning the ‘Identification 
of human and animal adenoviruses and polyomaviruses for determination of 
sources of fecal contamination in the environment’ (Hundesa et al., 2006). 
This paper discusses the detection of BPyV in ‘samples potentially affected 
by either porcine or bovine fecal contamination’, and documents that this is 
the ‘first time that….BPyV have been reported to occur in environmental 
samples’. The significance of this study to the MSc is unclear, although the 
number of papers published highlights the lack of research carried out on 
BPyV.  95 
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